US20160017058A1 - Bispecific antibodies and uses thereof - Google Patents

Bispecific antibodies and uses thereof Download PDF

Info

Publication number
US20160017058A1
US20160017058A1 US14/774,649 US201414774649A US2016017058A1 US 20160017058 A1 US20160017058 A1 US 20160017058A1 US 201414774649 A US201414774649 A US 201414774649A US 2016017058 A1 US2016017058 A1 US 2016017058A1
Authority
US
United States
Prior art keywords
antibody
fragment
bispecific
amino acids
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/774,649
Other languages
English (en)
Inventor
Chanhyuk Kim
Jun Y. AXUP
Peter G. Schultz
Travis Young
Stephanie PINKERTON
Quan Zhou
Yu Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
California Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, California Institute for Biomedical Research filed Critical Scripps Research Institute
Priority to US14/774,649 priority Critical patent/US20160017058A1/en
Assigned to THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH reassignment THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHULTZ, PETER G., CAO, YU, KIM, Chanhyuk, PINKERTON, Stephanie, YOUNG, TRAVIS
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHULTZ, PETER G., AXUP, JUN Y., ZHOU, QUAN, KIM, Chanhyuk
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE CORRECTIVE ASSIGNMENT TO CORRECT THE ADD FIFTH INVENTOR PREVIOUSLY RECORDED AT REEL: 032916 FRAME: 0477. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: ZHOU, QUAN, AXUP, JUN Y, CAO, YU, KIM, Chanhyuk, SCHULTZ, PETER G
Assigned to THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH reassignment THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTING OF INVENTOR YU CAO PREVIOUSLY RECORDED ON REEL 032916 FRAME 0631. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Assignors: PINKERTON, Stephanie, KIM, Chanhyuk, SCHULTZ, PETER G, YOUNG, TRAVIS
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHULTZ, PETER G., ZHOU, QUAN, AXUP, JUN Y., CAO, YU, KIM, Chanhyuk
Assigned to THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH reassignment THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PINKERTON, Stephanie, KIM, Chanhyuk, SCHULTZ, PETER G., YOUNG, TRAVIS
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: SCRIPPS RESEARCH INSTITUTE
Publication of US20160017058A1 publication Critical patent/US20160017058A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: SCRIPPS RESEARCH INSTITUTE
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • immunoglobulin constructs comprising one or more unnatural amino acids, methods of making such constructs, pharmaceutical compositions and medicaments comprising such constructs, and methods of using such constructs and compositions to prevent, inhibit, and/or treat a disease or condition in a subject.
  • Antibodies are natural proteins that the vertebrate immune system forms in response to foreign substances (antigens), primarily for defense against infection.
  • antibodies have been induced in animals under artificial conditions and harvested for use in therapy or diagnosis of disease conditions, or for biological research.
  • Each individual antibody producing cell produces a single type of antibody with a chemically defined composition, however, antibodies obtained directly from animal serum in response to antigen inoculation actually comprise an ensemble of non-identical molecules (e.g., polyclonal antibodies) made from an ensemble of individual antibody producing cells.
  • bispecific antibodies may bind to two or more different antigens.
  • a number of recombinant strategies have been developed to synthesize bispecific antibodies, which include single chain variable fragment (scFv)-derived formats such as diabodies, tandem diabodies, BiTes (bispecific T-cell engager), and DARTs (Dual Affinity Re-Targeting), as well as immunoglobulin G (IgG)-based formats such as Triomab, DVD-Ig (Dual Variable Domain antibodies), and two-in-one antibodies.
  • scFv single chain variable fragment
  • BiTes bispecific T-cell engager
  • DARTs Dual Affinity Re-Targeting
  • IgG immunoglobulin G
  • immunoglobulin constructs comprising one or more unnatural amino acids, methods of producing such constructs, and uses thereof.
  • bispecific antibodies comprising: an anti-CD3 antibody or anti-CD3 antibody fragment; a second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment is site-specifically connected to the second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may be site-specifically connected to the second antibody or antibody fragment by one or more linkers.
  • the second antibody or antibody fragment may comprise an anti-EGFRvIII antibody.
  • the second antibody or antibody fragment may comprise an anti-Her2 antibody.
  • the second antibody or antibody fragment may comprise an anti-CS1 antibody.
  • the second antibody or antibody fragment may comprise an anti-CLL-1 antibody.
  • the second antibody or antibody fragment may comprise an anti-CD33 antibody.
  • the second antibody or antibody fragment may comprise an anti-CD20 antibody.
  • the second antibody or antibody fragment may comprise an anti-ROR1 antibody.
  • the second antibody or antibody fragment may comprise an anti-CD44v6 antibody.
  • the second antibody or antibody fragment may comprise an anti-PVRL4 antibody.
  • the second antibody or antibody fragment may comprise an anti-IL13R ⁇ 2 antibody.
  • the second antibody or antibody fragment may comprise a bscWue1 antibody.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment comprises one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the bispecific antibody may be of a Formula I: X-L1′-Y or a Formula IA: Y-L1′-X, wherein: X comprises the anti-CD3 antibody or anti-CD3 antibody fragment; L1′ comprises the one or more linkers; and Y comprises the second antibody or antibody fragment.
  • X may comprise a human antibody or human antibody fragment.
  • X may comprise a humanized antibody or humanized antibody fragment.
  • X may comprise a human engineered antibody or human engineered antibody fragment.
  • X may comprise a fully human antibody or fully human antibody fragment.
  • X may comprise a chimeric antibody or portion thereof.
  • X may comprise a cross-species reactive antibody or a portion thereof.
  • the anti-CD3 antibody may be cross-species reactive with human and cynomolgus monkey.
  • X and/or Y may comprise one or more Fv.
  • X and/or Y may comprise one or more Fc.
  • X and/or Y may comprise one or more Fab.
  • X and/or Y may comprise one or more (Fab′)2.
  • X and/or Y may comprise one or more single chain Fv (scFv).
  • X and/or Y may comprise one or more diabodies.
  • X and/or Y may comprise one or more triabodies.
  • X and/or Y may comprise one or more tetrabodies.
  • X and/or Y may comprise one or more bifunctional hybrid antibodies.
  • X and/or Y may comprise one or more CDR1. X and/or Y may comprise one or more CDR2. X and/or Y may comprise one or more CDR3. X and/or Y may comprise one or more combinations of CDR's. X and/or Y may comprise one or more variable regions. X and/or Y may comprise one or more framework regions. X and/or Y may comprise one or more constant regions. X and/or Y may comprise one or more heavy chains. X and/or Y may comprise one or more light chains. X and/or Y may comprise one or more and variable regions. X and/or Y may comprise one or more alternative scaffold non-antibody molecules.
  • X and/or Y may comprise a combination of Fv, Fc, Fab, (Fab′)2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid antibodies, CDR1, CDR2, CDR3, combinations of CDR's, variable regions, framework regions, constant regions, heavy chains, light chains, and variable regions, alternative scaffold non-antibody molecules.
  • X and/or Y may comprise a Fab fragment.
  • the anti-CD3 antibody fragment may be UCHT1.
  • Y may comprise at least a portion of a Fab fragment.
  • Y may comprise at least a portion of an antibody or antibody fragment that binds to an antigen on a hematopoietic cell.
  • Y may comprise at least a portion of an antibody or antibody fragment that binds to an antigen on a myeloid cell.
  • Y may comprise at least a portion of an antibody or antibody fragment that binds to an antigen on a lymphocyte.
  • Y may comprise at least a portion of an antibody or antibody fragment that binds to an antigen on a B-cell or B-cell progenitor.
  • Y may comprise at least a portion of an antibody or antibody fragment that binds to an antigen on a cancerous cell.
  • Y may comprise at least a portion of an antibody selected from the group comprising an anti-CD20 antibody, an anti-EGFRvIII antibody, an anti-CS1 antibody, an anti-CLL-1 antibody and an anti-CD33 antibody.
  • Y may comprise at least a portion of a Fab fragment of an antibody selected from the group comprising an anti-CD20 antibody, an anti-EGFRvIII antibody, an anti-CS1 antibody, an anti-CLL-1 antibody and an anti-CD33 antibody.
  • Y may comprise at least a portion of an antibody selected from the group comprising an anti-ROR1 antibody, an anti-CD44v6 antibody, an anti-PVRL4 antibody, an anti-IL13R ⁇ 2 antibody and an anti-bscWue1 antibody.
  • Y may comprise at least a portion of Fab fragment of an antibody selected from the group comprising an anti-ROR1 antibody, an anti-CD44v6 antibody, an anti-PVRL4 antibody, an anti-IL13R ⁇ 2 antibody and a bscWue1 antibody.
  • Y may comprise at least a portion of an anti-Her2 antibody.
  • Y may comprise at least a portion of a Fab fragment of an anti-Her2 antibody.
  • Y may be selected form SEQ ID NOs: 3-16.
  • the bispecific antibody may further comprise a second linker.
  • the bispecific antibody may be of Formula II: X-L1-L2-Y or Formula IIA: Y-L2-L1-X, wherein: a L1′′ is coupled to X to produce a first intermediate of Formula III: X-L1′ or Formula IIIA: L1′-X, wherein X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; and L1′′ comprises a first linker before being coupled to X; L2′′ is coupled to Y to produce a second intermediate of Formula IV: Y-L2′ or Formula IVA: L2′-Y; wherein Y comprises at least a portion of a second antibody or antibody fragment and L2′′ comprises a second linker before being coupled to Y; and the first intermediate is coupled to the second intermediate.
  • L1′′ may comprise one or more chemical groups selected from an alkoxy-amine, hydrazine, aryl azide, alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, cyclooctyne, trans-cyclooctene, cyclopropene, norborene and disulfide.
  • chemical groups selected from an alkoxy-amine, hydrazine, aryl azide, alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbon
  • L2′′ may comprise one or more chemical groups selected from an alkoxy-amine, hydrazine, aryl azide, alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, cyclooctyne, trans-cyclooctene, cyclopropene, norborene and disulfide.
  • One terminus of L1′′ may comprise an alkoxy-amine.
  • L2′′ may comprise an alkoxy-amine.
  • One terminus of L1′′ may comprise an azide group.
  • One terminus of L1′′ may comprise an cyclooctyne group.
  • One terminus of L2′′ may comprise an azide group.
  • One terminus of L2′′ may comprise an cyclooctyne group.
  • X may be coupled to L1 by a covalent bond, ionic bond, or non-covalent bond.
  • Y may be coupled to L2 by a covalent bond, ionic bond, or non-covalent bond.
  • X may coupled to L1 by an oxime.
  • Y may be coupled to L2 by an oxime.
  • X-L1′ and L2′-Y may be linked through a reaction selected from a Huisgen-cycloaddition.
  • L2′-Y may be linked through a reaction selected from a Diels-Halder reaction.
  • L2′-Y may be linked through a reaction selected from a hetero Diels-Alder reaction and an enzyme-mediated reaction.
  • L1′-X and Y-L2′ may be linked through a reaction selected from a Huisgen-cycloaddition.
  • L1′-X and Y-L2′ may be linked through a reaction selected from a Diels-Halder reaction.
  • L1′-X and Y-L2′ may be linked through a reaction selected from a hetero Diels-Alder reaction.
  • L1′-X and Y-L2′ may be linked through a reaction selected from an enzyme-mediated reaction.
  • the enzyme-mediated reaction may comprise a transglutaminase reaction.
  • X-L1′ and L2′-Y may be linked through a copper-free [3+2] Huisgen-cycloaddition.
  • Y-L2′ and L1′-X may be linked through a copper-free [3+2] Huisgen-cycloaddition.
  • X-L1′ and L2′-Y may be linked through a disulfide or a maleimide.
  • Y-L2′ and L1′-X may be linked through a disulfide or a maleimide.
  • the distance between X and Y may be less than about 50 angstrom ( ⁇ ), about 45 angstrom ( ⁇ ), about 40 angstrom ( ⁇ ), about 35 angstrom ( ⁇ ), about 30 angstrom ( ⁇ ), about 25 angstrom ( ⁇ ), about 20 angstrom ( ⁇ ), about 15 angstrom ( ⁇ ), about 10 angstrom ( ⁇ ) or about 5 angstrom ( ⁇ ).
  • the one or more linkers may comprise one or more ethylene glycol subunits.
  • the bispecific antibodies disclosed herein may comprise one or more unnatural amino acids.
  • X may comprise one or more unnatural amino acids.
  • Y may comprise one or more unnatural amino acids.
  • the one or more unnatural amino acids may be site-specifically incorporated into X.
  • the one or more unnatural amino acids may be site-specifically incorporated into Y.
  • the one or more unnatural amino acids of X may be genetically encoded.
  • the one or more unnatural amino acids of Y may be genetically encoded.
  • the one or more unnatural amino acids of X may be genetically encoded by a codon selected from a nonsense codon, a stop codon, an umber codon, an ochre codon, an opal codon, a four-base codon and an amber codon.
  • the one or more unnatural amino acids of Y may be genetically encoded by a codon selected from a nonsense codon, a stop codon, an umber codon, an ochre codon, an opal codon, a four-base codon and an amber codon.
  • the one or more unnatural amino acids of X may comprise a p-acetylphenylalanine (pAcF).
  • the one or more unnatural amino acids of Y may comprise a p-acetylphenylalanine (pAcF).
  • the one or more unnatural amino acids of X may comprise selenocysteine.
  • the one or more unnatural amino acids of Y may comprise a selenocysteine.
  • the one or more unnatural amino cids may be p-fluorophenylalanine (pFPhe).
  • the one or more unnatural amino acids may be selected from the group comprising p-azidophenylalanine (pAzF), p-benzoylphenylalanine (pBpF), p-propargyloxyphenylalanine (pPrF), p-iodophenylalanine (pIF), p-cyanophenylalanine (pCNF), p-carboxylmethylphenylalanine (pCmF), 3-(2-naphthyl)alanine (NapA), p-boronophenylalanine (pBoF), o-nitrophenylalanine (oNiF), (8-hydroxyquinolin-3-yl)alanine (HQA), selenocysteine, and (2,2′-bipyridin-5-yl)alanine (BipyA
  • the one or more unnatural amino acids may be ⁇ -amino acids ( ⁇ 3 and ⁇ 2), homo-amino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, N-methyl amino acids, or a combination thereof.
  • the site-specific connection may occur via the one or more unnatural amino acids of X.
  • the site-specific connection may occur via the one or more unnatural amino acids of Y.
  • the purity of the bispecific antibody may be equal to or greater than 50%.
  • the purity of the bispecific antibody may be equal to or greater than 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 98%.
  • the homogeneity of the bispecific antibody may be equal to or greater than 50%.
  • the homogeneity of the bispecific antibody may be equal to or greater than 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 98%.
  • bispecific antibodies comprising connecting a plurality of anti-CD3 antibodies or anti-CD3 antibody fragments to a plurality of second antibodies or antibody fragments to produce a plurality of anti-CD3 bispecific antibodies, wherein at least 60% of the anti-CD3 bispecific antibodies are identical.
  • a bispecific antibodies of Formula II: X-L1′-L2′-Y or Formula IIA: Y-L2′-L1′-X comprising: coupling L1′′ to X to produce a first intermediate of Formula III: X-L1′ or Formula IIIA: L1′-X, wherein X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; and L1′′ comprises a first linker before being coupled to X, coupling L2′′ to Y to produce a second intermediate of Formula IV: Y-L2′ or Formula IVA: L2′-Y; wherein Y comprises at least a portion of a second antibody or antibody fragment and L2′′ comprises a second linker before being coupled to Y; and linking the first intermediate to the second intermediate, thereby producing the antibody of Formula II or HA.
  • Coupling L1′′ to X may comprise site-specific coupling of L1′′ to X.
  • Coupling L2′′ to Y may comprise site-specific coupling of L2′′ to Y.
  • the method may further comprise incorporating one or more unnatural amino acids into X.
  • the method may further comprise incorporating one or more unnatural amino acids into Y.
  • Incorporating one or more unnatural amino acids into X and/or Y may comprise modifying one or more amino acid residues in X and/or Y to produce one or more amber codons in X and/or Y.
  • the one or more unnatural amino acids may be incorporated into X and/or Y in response to an amber codon.
  • the one or more unnatural amino acids may be site-specifically incorporated into X and/or Y. Incorporating one or more unnatural amino acids may comprise the use of one or more tRNA synthetases.
  • the tRNA synthetase may be an aminoacyl tRNA synthetase.
  • the tRNA synthetase may be a mutant tRNA synthesis.
  • Incorporating one or more unnatural amino acids may comprise a tRNA/tRNA synthetase pair.
  • the tRNA/tRNA synthetase pair may comprise a tRNA/aminoacyl-tRNA synthetase pair.
  • the tRNA/tRNA synthetase pair may comprise a tRNATyr/tyrosyl-tRNA synthetase pair.
  • Coupling L1′′ to X may occur at the one or more unnatural amino acids in X.
  • Coupling L2′′ to Y may occur at the one or more unnatural amino acids in Y.
  • Coupling L1′′ to X and coupling L2′′ to Y may occur sequentially.
  • Coupling L1′′ to X and coupling L2 to Y may occur simultaneously.
  • Coupling L1′′ to X may occur prior to coupling L2′′ to Y.
  • Coupling L2′′ to Y may occur prior to coupling L1′′ to X.
  • Coupling L1′′ to X and/or coupling L2′′ to Y may comprise forming one or more oxime bonds between L1′′ and X and/or between L2′′ and Y.
  • Coupling L1′′ to X and/or coupling L2′′ to Y may comprise forming one or more stable bonds between L1′′ and X and/or between L2′′ and Y.
  • Coupling L1′′ to X and/or coupling L2′′ to Y may comprise forming one or more covalent bonds between L1′′ and X and/or between L2′′ and Y.
  • Coupling L1′′ to X and/or coupling L2′′ to Y may comprise forming one or more non-covalent bonds between L1′′ and X and/or between L2′′ and Y.
  • Coupling L1′′ to X and/or coupling L2′′ to Y may comprise forming one or more ionic bonds between L1′′ and X and/or between L2′′ and Y.
  • Linking the first intermediate to the second intermediate may comprise a Huisgen-cycloaddition.
  • Linking the first intermediate to the second intermediate may comprise a Diels-Halder reaction
  • Linking the first intermediate to the second intermediate may comprise a hetero Diels-Alder reaction
  • Linking the first intermediate to the second intermediate may comprise an enzyme-mediated reaction
  • Linking the first intermediate to the second intermediate may comprise a copper-free [3+2] Huisgen-cycloaddition reaction
  • Linking the first intermediate to the second intermediate may produce an oxime
  • Linking the first intermediate to the second intermediate may produce a tetrazole
  • Linking the first intermediate to the second intermediate may produce a Diels Alder adduct
  • Linking the first intermediate to the second intermediate may produce a hetero Diels Alder adduct
  • Linking the first intermediate to the second intermediate may produce an aromatic substitution reaction product
  • Linking the first intermediate to the second intermediate may produce a nucleophilic substitution reaction product
  • Linking the first intermediate to the second intermediate may produce a disulfide bridge
  • Linking the first intermediate to the second intermediate may produce a maleimide bridge.
  • the distance between X and Y may be less than or equal to 50, 45, 40, 35, 30, 25, or 20 angstroms ( ⁇ ).
  • the distance between X and Y may be greater than or equal to 5 angstroms ( ⁇ ).
  • compositions comprising a bispecific antibody, wherein the bispecific antibody comprises an anti-CD3 antibody or anti-CD3 antibody fragment; a second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment is site-specifically connected to the second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may be site-specifically connected to the second antibody or antibody fragment by one or more linkers.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment comprises one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient or a pharmaceutically acceptable carrier.
  • a bispecific antibody comprising administering a bispecific antibody, wherein the bispecific antibody comprises an anti-CD3 antibody or anti-CD3 antibody fragment; a second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment is site-specifically connected to the second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may be site-specifically connected to the second antibody or antibody fragment by one or more linkers.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment comprises one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the disease or condition may be a cancer.
  • the cancer may be a breast cancer.
  • the cancer may be a glioma or glioblastoma.
  • the cancer may be a multiple myeloma.
  • the cancer may be an acute myeloid leukemia (AML).
  • the cancer may be selected from an acute lymphoblastic leukemia (ALL), a B-cell chronic lymphocytic leukemia (B-CLL) and a mantle cell lymphoma (MCL).
  • ALL acute lymphoblastic leukemia
  • B-CLL B-cell chronic lymphocytic leukemia
  • MCL mantle cell lymphoma
  • the disease or condition may be a pathogenic infection.
  • the disease or condition may be an inflammatory disease, an autoimmune disease or a metabolic disease.
  • the bispecific antibody or pharmaceutical composition may be administered by parenteral administration.
  • the parenteral administration may comprise intravenous administration, subcutaneous administration, intraperitoneal administration, intramuscular administration, intravascular administration, intrathecal administration, intravitreal administration, or infusion.
  • the bispecific antibody or pharmaceutical composition may be administered by a microneedle device.
  • the bispecific antibody or pharmaceutical composition may be administered by topical, oral, or nasal administration.
  • FIG. 1 depicts a ribbon diagram of a UCHT1-Fab fragment.
  • FIG. 2A depicts the structure of p-acetylphenylaline.
  • FIG. 2B depicts the structure of bifunctional ethylene glycol linkers
  • FIG. 2C depicts a general scheme for the generation of bispecific antibodies
  • FIG. 3A-E depict ESI-MS analysis of Fab fragments before linker and after linker conjugation.
  • FIG. 3B depicts Herceptin Fab-(PEG) 4 -Az;
  • FIG. 3C depicts Herceptin Fab-(PEG) 4 -Octyne;
  • FIG. 3E depicts UCHT1 Fab-(PEG) 4 -Octyne.
  • FIG. 3F-J depict deconvoluted mass spectrum of Fab fragments before and after linker conjugation.
  • FIG. 3G depicts Herceptin Fab-(PEG) 4 -Az;
  • FIG. 3H depicts Herceptin Fab-(PEG) 4 -Octyne;
  • FIG. 3J depicts UCHT1 Fab-(PEG) 4 -Octyne.
  • FIG. 4A-B depict an SDS-PAGE gel ( FIG. 4A ) and size exclusion chromatography FPLC trace ( FIG. 4B ) of the anti-HER2/anti-CD3 heterodimer.
  • FIG. 5A-D depict bispecific binding of anti-HER2/anti-CD3 Fab heterodimer.
  • FACS-based binding assay with Jurkat (CD3+) cells FIG. 5A
  • SK-BR-3 HER2+
  • FIG. 5B FIG. 5C-D depicts fluorescence microscope images of the interaction between SK-BR3 cells (larger, dark grey circles, highlighted by the vertical arrows in FIG. 5C ) and Jurkat cells (smaller, light grey circles, highlighted by the horizontal arrows in FIG. 5C-D ) in the presence of the conjugated anti-HER2/anti-CD3 heterodimer ( FIG. 5C ) or in the presence of a mixture of unconjuaged anti-HER2 Fab and anti-CD3 Fab at a 1:1 ratio ( FIG. 5D ).
  • FIG. 6 depicts a graph of dose-dependent cytoxicity with MDA-MB-435/HER2+ cells in the presence of human PBMCs and antibody heterodimer.
  • FIG. 7A-D depict microscopic images from a cytoxicity assay.
  • FIG. 7A depicts microscopic images from a cytoxicity assay with HER2 ⁇ cells treated with a Fab mixture
  • FIG. 7B depicts microscopic images from a cytoxicity assay with HER2 ⁇ cells treated with a bispecific antibody heterodimer
  • FIG. 7C depicts microscopic images from a cytoxicity assay with HER2+ cells treated with a Fab mixture
  • FIG. 7D depicts microscopic images from a cytoxicity assay with HER2+ cells treated with a bispecific antibody heterodimer.
  • FIG. 8 depicts growth curves of MDA-MB-435/HER2+ cells premixed with hPBMC and Matrigel.
  • the ratios of the cancer cells to hPBMCs were 1:1 (square), 1:2 (triangle) and 1:5 (x).
  • FIG. 9 depicts a graph of the tumor volume of a MDA-MB-435/HER2+ tumor treated with a bispecific antibody (circle), Fab mixture (square) or PBS (triangle).
  • FIG. 10 depicts IVIS imaging of two heterodimer treated mice (left two) and two unconjugated Fab treated mice (right two).
  • FIG. 11 depicts excised tumors or MatriGel from a preventative anti-HER2/anti-CD3 Fab heterodimer study.
  • FIG. 12 shows a general scheme for synthesizing bifunctional linkers.
  • FIG. 13 depicts a graph of the cytoxicity of Ramos cells treated with an anti-CD20/anti-CD3 bispecific antibody or treated with unconjugated Fab fragments.
  • FIG. 14 depicts a graph of the cytoxicity of A549 cells treated with an anti-EGFR/anti-CD3 bispecific antibody or treated with unconjugated Fab fragments.
  • FIG. 15 depicts a graph of the cytoxicity of HT29 cells treated with an anti-EGFR/anti-CD3 bispecific antibody or treated with unconjugated Fab fragments.
  • FIG. 16 depicts a graph of the cytoxicity of AGS cells treated with an anti-EGFR/anti-CD3 bispecific antibody or treated with unconjugated Fab fragments.
  • FIG. 17A depticts the antigen binding fragments (Fab's) of anti-CS1 (huLuc3) and anti-CD3 (UCHT1) antibodies that were individually expressed in E. coli with pAcF suppressing a TAG mutation (at Serine 202) purified and conjugated using the optimized heterobifunctional linkers in FIG. 17B .
  • Fab's antigen binding fragments
  • FIG. 17B depicts heterobifunctional linkers.
  • the Tet-TEG-ONH 2 linker was conjugated to CS1 using the aminooxy functionality of the linker and the ketone of the pAcF incorporated at Serine 202 in an oxime ligation.
  • the TCO-TEG-ONH 2 was conjugated to was conjugated to UCHT1 using the aminooxy functionality of the linker and the ketone of pAcF incorporated at Serine 202 in an oxime ligation.
  • the two proteins were subsequently “clicked” together to create the BiFab shown in FIG. 17A .
  • FIG. 17C shows the cytotoxicity of the BiFab, unconjugated monomers, and unconjugated monomers mixed was assayed using freshly purified, crude, human peripheral blood monocytes (PBMCs) against MM.1S cells in an overnight assay. Cytotoxicity results were readout by an LDH assay following standard protocols.
  • PBMCs peripheral blood monocytes
  • FIG. 18 depicts exemplary linkers.
  • FIG. 19A shows masses of CS1 Fab S202pAcF and UCHT1 Fab S202pAcF prior to conjugation to their respective linkers.
  • FIG. 19B shows masses of CS1 Fab S202pAcF and UCHT1 Fab S202pAcF conjugated to the Tet-TEG-ONH2 (tet) and TCO-Tet-ONH2 (TCO) linkers respectively.
  • FIG. 19C shows the mass of the CS1 ⁇ UCHT1 biFab.
  • FIG. 20A shows selective binding of anti CLL-1/anti-CD3 biFab to CLL-1+HL-60 cells.
  • FIG. 20B shows selective binding of anti-CD33/anti-CD3 biFab to CD33+HL-60 cells.
  • FIG. 21A shows cytotoxicity of anti-CLL-1/anti-CD3 biFab towards CLL-1+HL-60 cells.
  • FIG. 21B shows cytotoxicity of anti-CD33/anti-CD3 biFab towards CD33+HL-60 cells.
  • FIG. 22A shows HL-60 IFN gamma release due to anti-CD33/anti-CD3 biFab or anti-CLL-1/anti-CD3 biFab.
  • FIG. 22B shows HL-60 IL-2 release due to anti-CD33/anti-CD3 biFab or anti-CLL-1/anti-CD3 biFab.
  • FIG. 23 shows expression and purification of UCHT1/anti-EGFRvIII biFabs.
  • Antigen binding fragments (Fab's) of anti-EGFR/EGFRvIII (hu806) and anti-CD3 (UCHT1) antibodies were individually expressed in E. coli with pAcF suppressing a TAG mutation (at Serine 202 LC, hu806 or Lysine 138 HC, UCHT1) purified and conjugated using optimized heterobifunctional linkers.
  • FIG. 24A shows masses of Hu806 Fab S202pAcF and UCHT1 Fab S202pAcF prior to conjugation to their respective linkers.
  • FIG. 24B shows masses of Hu806 Fab S202pAcF and UCHT1 Fab S202pAcF conjugated to the Tet-TEG-ONH2 and TCO-Tet-ONH2 linkers respectively.
  • FIG. 24C shows the mass of the Hu806-UCHT1 BiFab.
  • FIG. 25 shows cytotoxicity of the Hu806-UCHT1 BiFab, unconjugated monomers, and unconjugated monomers mixed was assayed using freshly purified activated human peripheral blood monocytes (PBMCs) against A431 cells in an overnight assay. Cytotoxicity results were readout by an LDH assay following standard protocols.
  • PBMCs peripheral blood monocytes
  • the terms “immunoglobulin”, “immunoglobulin construct” and “bispecific antibody” are used interchangeably.
  • the bispecific antibody comprises one or more unnatural amino acids.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and a second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment are site-specifically connected.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and an anti-EGFRvIII antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the anti-EGFRvIII antibody or antibody fragment are site-specifically connected.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and/or the anti-EGFRvIII antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and an anti-Her2 antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the anti-Her2 antibody or antibody fragment are site-specifically connected.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and/or the anti-Her2 antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and an anti-CS-1 antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the anti-CS-1 antibody or antibody fragment are site-specifically connected.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and/or the anti-CS-1 antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and an anti-CLL-1 antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the anti-CLL-1 antibody or antibody fragment are site-specifically connected.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and/or the anti-CLL-1 antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the bispecific antibody may comprise an anti-CD3 antibody or anti-CD3 antibody fragment and an anti-CD33 antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment and the anti-CD33 antibody or antibody fragment are site-specifically connected.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and/or the anti-CD33 antibody or antibody fragment may comprise one or more unnatural amino acids.
  • X may comprise one or more unnatural amino acids.
  • Y may comprise one or more unnatural amino acids.
  • X and Y may comprise one or more unnatural amino acids.
  • a bispecific antibody of Formula II X-L1-L2-Y or an antibody of Formula IIA: Y-L2-L1-X, wherein (a) X comprises at least a portion of an anti-CD3 antibody or anti-CD3 antibody fragment; (b) L1 and L2 are linkers; and (c) Y comprises at least a portion of a second antibody or antibody fragment, wherein X is site-specifically linked to Y by the linkers.
  • X may comprise one or more unnatural amino acids.
  • Y may comprise one or more unnatural amino acids.
  • X and Y may comprise one or more unnatural amino acids.
  • the bispecific antibodies disclosed herein may bind to two or more different antigens.
  • the bispecific antibody may comprise an antibody, antibody fragment, or combination thereof.
  • the bispecific antibody may comprise an immunoglobulin-immunoglobulin (Ig-Ig) construct, wherein X comprises an immunoglobulin and Y comprises an immunoglobulin.
  • the bispecific antibody may comprise an immunoglobulin-Fab (Ig-Fab) construct, wherein X comprises an immunoglobulin and Y comprises a Fab fragment.
  • the bispecific antibody may comprise a Fab-Fab construct, wherein X comprises a Fab fragment and Y comprises a Fab fragment.
  • linkers e.g., L1, L2
  • antibody fragment may refer to any form of an antibody other than the full-length form.
  • Antibody fragments herein include antibodies that are smaller components that exist within full-length antibodies, and antibodies that have been engineered.
  • Antibody fragments include, but are not limited to, Fv, Fc, Fab, and (Fab′)2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid antibodies, CDR1, CDR2, CDR3, combinations of CDR's, variable regions, framework regions, constant regions, heavy chains, light chains, alternative scaffold non-antibody molecules, and bispecific antibodies.
  • Fab′ single chain Fv
  • the antibodies disclosed herein may be human, fully human, humanized, human engineered, non-human, and/or chimeric.
  • the antibody of Formula I may be a humanized antibody.
  • the antibody of Formula II is a chimeric antibody.
  • the antibodies disclosed herein may be based on or derived from human, fully human, humanized, human engineered, non-human and/or chimeric antibodies.
  • X and/or Y of Formula IA may be based on or derived from a human engineered antibody.
  • X and/or Y of Formula IIA may be based on or derived from a non-human antibody.
  • Non-human antibody may be humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
  • a humanized antibody comprises one or more variable domains in which CDRs (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
  • a humanized antibody optionally also comprises at least a portion of a human constant region.
  • some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.
  • Chimeric antibodies may refer to antibodies created through the joining of two or more antibody genes which originally encoded for separate antibodies.
  • a chimeric antibody may comprise at least one amino acid from a first antibody and at least one amino acid from a second antibody, wherein the first and second antibodies are different.
  • the antibodies disclosed herein may comprise antibody sequences from two or more different antibodies.
  • X of the antibodies disclosed herein e.g., antibody of Formula I, IA, II or HA
  • Y of the antibodies disclosed herein e.g., antibody of Formula I, IA, II or IIA
  • the first and second antibodies are different.
  • X of the antibodies disclosed herein may be a chimeric antibody.
  • Y of the antibodies disclosed herein may be a chimeric antibody.
  • the two or more different antibodies may be from the same species.
  • the species may be a bovine species, human species, or murine species.
  • the two or more different antibodies may be from the same type of animal.
  • the two or more different antibodies may be from a cow.
  • the two or more different antibodies may be from a human.
  • the two or more different antibodies are from different species.
  • the two or more different antibodies are from a human species and bovine species.
  • the two or more different antibodies are from a bovine species and a non-bovine species.
  • the two or more different antibodies are from a human species and a non-human species.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise at least a portion of a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 60% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 70% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 80% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 85% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence comprising five or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence comprising 6, 7, 8, 9, 10 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence comprising 15, 16, 17, 18, 19, 20 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence comprising 25, 30, 35, 40, 45, 50 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise a sequence comprising 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the amino acids may be consecutive.
  • the amino acids may be non-consecutive.
  • the second antibody or antibody fragment may comprise at least a portion of a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 60% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 70% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 80% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 85% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence comprising five or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence comprising 6, 7, 8, 9, 10 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence comprising 15, 16, 17, 18, 19, 20 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence comprising 25, 30, 35, 40, 45, 50 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the second antibody or antibody fragment may comprise a sequence comprising 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the amino acids may be consecutive.
  • the amino acids may be non-consecutive.
  • the antibodies disclosed herein may be based on or derived from an antibody or antibody fragment from a mammal, bird, fish, amphibian or reptile.
  • Mammals include, but are not limited to, carnivores, rodents, elephants, marsupials, rabbits, bats, primates, seals, anteaters, cetaceans, odd-toed ungulates and even-toed ungulates.
  • the mammal may be a human, non-human primate, mouse, sheep, cat, dog, cow, horse, goat, or pig.
  • the mammal may be a human.
  • the mammal may be a cynomolgus monkey.
  • Birds include, but are not limited to, albatrosses, hummingbirds, eagles, ostriches, cardinals, kiwis, and penguins.
  • Fish may be cartilaginous fishes, ray-finned fishes, or lobe-fined fishes.
  • Amphibians may include, but are not limited to, newts, salamanders, frogs and toads.
  • reptiles include, but are not limited to, turtles, squamates, crocodiles and tuataras. Squamates may include amphisbaenians, lizards and snakes.
  • the bispecific antibodies of Formulas I, IA, II, and/or IIA disclosed herein may comprise X, wherein X comprises at least a portion of an anti-CD3 antibody or anti-CD3 antibody fragment comprising one or more unnatural amino acids.
  • X may comprise an entire anti-CD3 antibody.
  • the anti-CD3 antibody may be UCHT1.
  • X may comprise at least a portion of an anti-CD3 antibody.
  • X may comprise at least a portion of a monoclonal anti-CD3 antibody.
  • X may comprise at least a portion of a CD3 polyclonal antibody.
  • X may comprise at least a portion of a multivalent anti-CD3 antibody.
  • X may comprise an anti-CD3 antibody.
  • X may comprise at least a portion of a Fab fragment of an anti-CD3 antibody.
  • X may comprise an antibody fragment of an anti-CD3 antibody.
  • X may comprise at least a portion of an anti-CD3 antibody.
  • the portion of the antibody may comprise an antibody fragment.
  • Antibody fragments include, but are not limited to, Fv, Fc, Fab, and (Fab′)2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid antibodies, CDR1, CDR2, CDR3, combinations of CDR's, variable regions, framework regions, constant regions, heavy chains, light chains, alternative scaffold non-antibody molecules, and bispecific antibodies.
  • X may comprise at least a portion of a heavy chain (HC) of an anti-CD3 antibody.
  • X may comprise at least a portion of a light chain (LC) of a anti-CD3 antibody.
  • X may comprise at least a portion of a variable region of an anti-CD3 antibody.
  • X may comprise at least a portion of a constant region of an anti-CD3 antibody.
  • X may comprise an antibody or antibody fragment that binds to a portion of CD3.
  • the portion of CD3 may comprise a CD3 gamma chain or a portion thereof.
  • the portion of CD3 may comprise a CD3 delta chain or a portion thereof.
  • the portion of CD3 may comprise a CD3 epsilon chain or a portion thereof.
  • the portion of CD3 may comprise a combination of a CD3 gamma chain, a CD3 delta chain and a CD3 epsilon chain.
  • X may comprise at least a portion of a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 60% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 70% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 80% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 85% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence comprising five or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence comprising 6, 7, 8, 9, 10 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence comprising 15, 16, 17, 18, 19, 20 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence comprising 25, 30, 35, 40, 45, 50 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • X may comprise a sequence comprising 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 1-2.
  • the amino acids may be consecutive.
  • the amino acids may be non-consecutive.
  • X may comprise an antibody or at least a portion of an antibody that is a human, fully human, humanized, human engineered, non-human, or chimeric antibody.
  • X may comprise an antibody or at least a portion of an antibody that is a mammalian antibody.
  • X may comprise an antibody or at least a portion of an antibody that is a non-mammalian antibody.
  • X may comprise an antibody or at least a portion of an antibody that is cross-reactive.
  • X may comprise an antibody or at least a portion of an antibody that is species cross-reactive with human and cynomolgus monkey.
  • X may comprise a sequence based on or derived from one or more anti-CD3 antibody and/or anti-CD3 antibody fragment sequences.
  • X may comprise a sequence that is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more homologous to a sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments.
  • X may comprise a sequence that is at least about 70% homologous to a sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments.
  • X may comprise a sequence that is at least about 80% homologous to a sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments. X may comprise a sequence that is at least about 90% homologous to a sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments. X may comprise a sequence that is at least about 95% homologous to a sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments. The sequence may be a peptide sequence. Alternatively, the sequence is a nucleotide sequence.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 20, 17, 15, 12, 10, 8, 6, 5, 4 or fewer amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 4 or fewer amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 3 or fewer amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 2 or fewer amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 1 or fewer amino acids.
  • the amino acids may be consecutive, nonconsecutive, or a combination thereof.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 3 consecutive amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 2 non-consecutive amino acids.
  • X may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 5 amino acids, wherein 2 of the amino acids are consecutive and 2 of the amino acids are non-consecutive.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 15 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 12 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or CD3 antibody fragments by less than or equal to about 9 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 6 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 4 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 3 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 2 or fewer nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than or equal to about 1 or fewer nucleotides or base pairs.
  • the nucleotides or base pairs may be consecutive, nonconsecutive, or a combination thereof.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 3 consecutive nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 2 non-consecutive nucleotides or base pairs.
  • X may be encoded by a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more anti-CD3 antibodies and/or anti-CD3 antibody fragments by less than about 5 nucleotides or base pairs, wherein 2 of the nucleotides or base pairs are consecutive and 2 of the nucleotides or base pairs are non-consecutive.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by one or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by two or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by three or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by four or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by five or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by six or more amino acid substitutions.
  • the peptide sequence of X may differ from the peptide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 15, 17, 20, 25 or more amino acid substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by one or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by two or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by three or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by four or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by five or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by six or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by nine or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by twelve or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by fifteen or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by eighteen or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of X may differ from the nucleotide sequence of the anti-CD3 antibody or anti-CD3 antibody fragment that it is based on and/or derived from by 20, 22, 24, 25, 27, 30 or more nucleotide and/or base pair substitutions.
  • X may comprise one or more unnatural amino acids.
  • X may comprise two or more unnatural amino acids.
  • X may comprise three or more unnatural amino acids.
  • X may comprise four or more unnatural amino acids.
  • X may comprise 5, 6, 7, 8, 9, 10 or more unnatural amino acids.
  • X may be coupled to one or more linkers. X may be linked to Y by one or more linkers. X may be linked to Y by two or more linkers. X may be linked to Y by three or more linkers.
  • the bispecific antibodies of Formulas I, IA, II, and/or IIA disclosed herein may comprise Y, wherein Y comprises at least a portion of an antibody or antibody fragment.
  • Y may comprise an entire antibody.
  • Y may comprise at least a portion of antibody.
  • Y may comprise at least a portion of a monoclonal antibody.
  • Y may comprise at least a portion of a polyclonal antibody.
  • Y may comprise at least a portion of a multivalent antibody.
  • Y may comprise at least a portion of an antibody.
  • the portion of the antibody may comprise an antibody fragment.
  • Antibody fragments include, but are not limited to, Fv, Fc, Fab, and (Fab′)2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid antibodies, CDR1, CDR2, CDR3, combinations of CDR's, variable regions, framework regions, constant regions, heavy chains, light chains, alternative scaffold non-antibody molecules, and bispecific antibodies.
  • Y may comprise a Fab fragment.
  • Y may comprise at least a portion of a heavy chain (HC) of an antibody.
  • Y may comprise at least a portion of a light chain (LC) of an antibody.
  • Y may comprise at least a portion of a variable region of an antibody.
  • Y may comprise at least a constant region of an antibody.
  • Y may comprise at least a portion of a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 60% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 70% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 80% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 50% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 85% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence comprising five or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence comprising 6, 7, 8, 9, 10 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence comprising 15, 16, 17, 18, 19, 20 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence comprising 25, 30, 35, 40, 45, 50 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • Y may comprise a sequence comprising 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids based on or derived from a sequence selected from SEQ ID NOs: 3-16.
  • the amino acids may be consecutive.
  • the amino acids may be non-consecutive.
  • the Y may comprise at least a portion of an antibody.
  • the antibody may be an anti-CD20 antibody.
  • the antibody may be an anti-EGFR antibody.
  • the anti-EGFR antibody may be an anti-Her1 antibody.
  • the anti-EGFR antibody may be an anti-Her2 antibody.
  • the anti-EGFR antibody may be an anti-Her3 antibody.
  • the anti-EGFR antibody may be an anti-Her4 antibody.
  • the antibody may be an anti-EGFR antibody wherein the anti-EGFR antibody specifically binds a mutated EGFR.
  • the mutated EGFR may be EGFRvIII.
  • the antibody may bind a cell adhesion molecule.
  • the antibody may be an anti-CS1 antibody.
  • the anti-CS1 antibody may comprise elotozumab, also referred to as HuLuc63.
  • the anti-CS1 antibody may be humanized.
  • the antibody may bind a receptor.
  • the antibody may be an anti-CLL-1 antibody.
  • the antibody may be an anti-CD33 antibody.
  • the antibody may be an anti-ROR antibody.
  • the ROR antibody may be an anti-ROR1 antibody.
  • the antibody may be an anti-CD44 antibody.
  • the anti-CD44 antibody may be an anti-CD44v6 antibody.
  • the antibody may be an anti-PVRL4 antibody.
  • the antibody may be an anti-interleukin receptor (ILR) antibody.
  • ILR anti-interleukin receptor
  • the interleukin receptor antibody may bind to an ILR selected from an IL1R, an IL2R, an IL3R, an IL4R, an IL5R, an IL6R, an IL7R, an IL8R, an IL9R, an IL10R, an IL11R, an IL12R, an IL13R, an IL14R, an IL15R and an IL17R.
  • the interleukin receptor antibody may bind to IL13R ⁇ 2.
  • the interleukin receptor antibody may be an anti-IL13R ⁇ 2 antibody.
  • the antibody may be a bispecific single chain (bsc) antibody.
  • the bsc antibody may be a bscWue-1 antibody.
  • Y may comprise a Fab fragment of an antibody.
  • Y may comprise a Fab fragment of an anti-B cell receptor antibody.
  • Y may comprise a Fab fragment of an anti-CD20 antibody.
  • Y may comprise a Fab fragment of an anti-EGFR antibody.
  • Y may comprise a Fab fragment of an anti-Her2 antibody.
  • Y may comprise a Fab fragment of an anti-EGFRvIII antibody.
  • Y may comprise a Fab fragment of an anti-CS1 antibody.
  • Y may comprise a Fab fragment of an anti-CLL-1 antibody.
  • Y may comprise a Fab fragment of an anti-CD33 antibody.
  • Y may comprise a Fab fragment of an anti-ROR1 antibody.
  • Y may comprise a Fab fragment of an anti-CD44v6 antibody.
  • Y may comprise a Fab fragment of an anti-PVRL4 antibody.
  • Y may comprise a Fab fragment of an anti-IL13R ⁇ 2 antibody.
  • Y may comprise an antibody or antibody fragment that binds to at least a portion of a receptor on a cell.
  • Y may comprise an antibody or antibody fragment that binds to at least a portion of a co-receptor on a cell.
  • Y may comprise an antibody or antibody fragment that binds to at least a portion of a co-receptor on a B cell.
  • Y may comprise an antibody or antibody fragment that binds to at least a portion of an antigen or cell surface marker on a cell.
  • the cell may be a hematopoietic cell.
  • the hematopoietic cell may be a myeloid cell.
  • the myeloid cell may be an erythrocyte, thrombocyte, neutrophil, monocyte, macrophage, eosinophil, basophil, or mast cell.
  • the cell may be a lymphoid cell.
  • the hematopoietic cell may be a lymphoid cell.
  • the lymphoid cell may be a B-cell, T-cell, or NK-cell.
  • the hematopoietic cell may be a leukocyte.
  • the hematopoietic cell may be a lymphocyte.
  • the cell may be a cancerous cell.
  • the cell may be a tumor cell.
  • the cell may be a leukemic cell.
  • the cell may be a non-tumor cell.
  • the cell may be a prostate cell.
  • the cell may be a breast cell.
  • the cell may be a glial cell.
  • the cell may be a liver cell, kidney cell, lung cell, cardiac cell, muscle cell, nerve cell, neuron, brain cell, epithelial cell, esophageal cell.
  • the Y may comprise an antibody or antibody fragment that binds to a receptor on a cell.
  • the receptor may be a growth factor receptor.
  • the growth factor receptor may be an epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR) or fibroblast growth factor receptor (FGFR).
  • EGFR may be EGFR1.
  • the EGFR may be Her2.
  • the EGFR may be Her3 or Her4.
  • the EGFR may have a mutation.
  • the EGFR may be EGFRvIII.
  • the receptor may be an interleukin receptor (ILR).
  • ILR interleukin receptor
  • the interleukin receptor may be selected from IL1R, an IL2R, an IL3R, an IL4R, an IL5R, an IL6R, an IL7R, an IL8R, an IL9R, an IL10R, an IL11R, an IL12R, an IL13R, an IL14R, an IL15R and an IL17R.
  • the interleukin receptor may be IL13R ⁇ 2.
  • Y may comprise an antibody or antibody fragment that binds to an antigen or cell surface marker on a hematopoietic cell.
  • Y may comprise an antibody or antibody fragment that binds to an antigen or cell surface marker on a B-cell.
  • the antigen or cell surface marker on the B-cell may be a B-lymphocyte antigen CD20 (CD20).
  • the Y may comprise an antibody or antibody fragment that binds to a differentiation antigen.
  • the differentiation antigen may be a CD44.
  • the CD44 may be CD44v6.
  • the differentiation antigen may be CD33.
  • CD33 may be highly expressed on cells of an acute myeloid leukemia. CD33 may be expressed on a cancer stem cell.
  • Y may comprise an antibody or antibody fragment that binds to a cell surface protein.
  • the cell surface protein may be a cell adhesion molecule.
  • the cell adhesion molecule may be a cell surface glycoprotein.
  • the cell surface glycoprotein may be CS1, also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24.
  • CS1 may co-localize with CD138.
  • the cell adhesion molecule may be PVRL4, also referred to as Nectin 4.
  • Y may comprise an antibody or antibody fragment that binds to C-type lectin-like molecule-1.
  • Y may comprise an antibody or antibody fragment that binds a receptor tyrosine kinase-like orphan receptor (ROR).
  • the ROR may be ROR1.
  • Y may comprise a bispecific single chain monoclonal antibody.
  • the bispecific single chain monoclonal antibody may be bscWue1.
  • Y may comprise an antibody or at least a portion of an antibody that is a human, fully human, humanized, human engineered, non-human, or chimeric antibody.
  • Y may comprise an antibody or at least a portion of an antibody that is a mammalian antibody.
  • Y may comprise an antibody or at least a portion of an antibody that is a non-mammalian antibody.
  • Y may comprise a sequence based on or derived from one or more antibodies and/or antibody fragments sequences.
  • Y may comprise a sequence that is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more homologous to a sequence based on or derived from one or more antibodies and/or antibody fragments.
  • Y may comprise a sequence that is at least about 70% homologous to a sequence based on or derived from one or more antibodies and/or antibody fragments.
  • Y may comprise a sequence that is at least about 80% homologous to a sequence based on or derived from one or more antibodies and/or antibody fragments.
  • Y may comprise a sequence that is at least about 90% homologous to a sequence based on or derived from one or more antibodies and/or antibody fragments. Y may comprise a sequence that is at least about 95% homologous to a sequence based on or derived from one or more antibodies and/or antibody fragments.
  • the sequence may be a peptide sequence. Alternatively, the sequence is a nucleotide sequence.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 20, 17, 15, 12, 10, 8, 6, 5, 4 or fewer amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 4 or fewer amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 3 or fewer amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 2 or fewer amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 1 or fewer amino acids.
  • the amino acids may be consecutive, nonconsecutive, or a combination thereof.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than about 3 consecutive amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than about 2 non-consecutive amino acids.
  • Y may comprise a peptide sequence that differs from a peptide sequence based on or derived from one or more antibodies or antibody fragments by less than about 5 amino acids, wherein 2 of the amino acids are consecutive and 2 of the amino acids are non-consecutive.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 15 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 12 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 9 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 6 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 4 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 3 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 2 or fewer nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than or equal to about 1 or fewer nucleotides or base pairs.
  • the nucleotides or base pairs may be consecutive, nonconsecutive, or a combination thereof.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than about 3 consecutive nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than about 2 non-consecutive nucleotides or base pairs.
  • Y may comprise a nucleotide sequence that differs from a nucleotide sequence based on or derived from one or more antibodies or antibody fragments by less than about 5 nucleotides or base pairs, wherein 2 of the nucleotides or base pairs are consecutive and 2 of the nucleotides or base pairs are non-consecutive.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by one or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by two or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by three or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by four or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by five or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by six or more amino acid substitutions.
  • the peptide sequence of Y may differ from the peptide sequence of the antibody or antibody fragment that it is based on and/or derived from by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 15, 17, 20, 25 or more amino acid substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by one or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by two or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by three or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by four or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by five or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by six or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by nine or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by twelve or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by fifteen or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by eighteen or more nucleotide and/or base pair substitutions.
  • the nucleotide sequence of Y may differ from the nucleotide sequence of the antibody or antibody fragment that it is based on and/or derived from by 20, 22, 24, 25, 27, 30 or more nucleotide and/or base pair substitutions.
  • Y may comprise one or more unnatural amino acids.
  • Y may comprise two or more unnatural amino acids.
  • Y may comprise three or more unnatural amino acids.
  • Y may comprise four or more unnatural amino acids.
  • Y may comprise 5, 6, 7, 8, 9, 10 or more unnatural amino acids.
  • Y may be coupled to one or more linkers. Y may be linked to X by one or more linkers. Y may be linked to X by two or more linkers. Y may be linked to X by three or more linkers.
  • the distance between X and Y may be between about 1 angstroms ( ⁇ ) to about 120 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 5 angstroms ( ⁇ ) to about 105 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 10 angstroms ( ⁇ ) to about 100 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 10 angstroms ( ⁇ ) to about 90 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 10 angstroms ( ⁇ ) to about 80 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 10 angstroms ( ⁇ ) to about 70 angstroms ( ⁇ ).
  • the distance between X and Y may be between about 15 angstroms ( ⁇ ) to about 45 angstroms ( ⁇ ).
  • the distance between X and Y may be equal to or greater than about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 27, 30 or more angstroms.
  • the distance between X and Y may be equal to or greater than about 10 angstroms.
  • the distance between X and Y may be equal to or greater than about 15 angstroms.
  • the distance between X and Y may be equal to or greater than about 20 angstroms.
  • the distance between X and Y may be equal to or less than about 110, 100, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30 or fewer angstroms.
  • the distance between X and Y may be equal to or less than about 100 angstroms.
  • the distance between X and Y may be equal to or less than about 80 angstroms.
  • the distance between X and Y may be equal to or less than about 60 angstroms.
  • the distance between X and Y may be equal to or less than about 40 angstroms.
  • the bispecific antibodies disclosed herein may comprise one or more linkers (e.g., L1, L2).
  • a linker may refer to a linker before it is coupled, reacted or linked to an antibody, antibody fragment, or another linker (e.g. L1”, L2”), a linker that is coupled, reacted or linked to an antibody or antibody fragment to produce an intermediate (e.g. X-L1′, L1′-X, Y-L2′, L2′-Y) or a linker in a bispecific antibody (e.g. X-L1-Y, X-L1-L2-Y, Y-L2-L1-X).
  • the antibodies disclosed herein may comprise two or more linkers.
  • the antibodies disclosed herein may comprise three or more linkers.
  • the antibodies disclosed herein may comprise 4, 5, 6, 7 or more linkers.
  • the linker may comprise one or more termini.
  • the linker may comprise two termini.
  • the one or more termini may have a similar orthogonal reactivity.
  • the one or more termini may have a different orthogonal reactivity.
  • the one or more linkers may comprise one or more reactive functional groups that may react with a complementary reactive functional group on another antibody or linker.
  • the linker may be a bifunctional linker.
  • the bifunctional may comprise BCN-TEG-ONH 2 , as depicted in FIG. 18 .
  • the bifunctional linker may comprise N 3 -TEG-ONH 2 , as depicted in FIG. 18 .
  • the bifunctional linker may be heterobifunctional, as exemplified in FIG. 17B .
  • the heterobifunctional linker may be Tet-TEG-ONH 2 or a derivation thereof.
  • the heterobifunctional linker may be TCO-TEC-ONH 2 or a derivation thereof.
  • the linker may comprise ethylene glycol.
  • the linker may be a bifunctional ethylene glycol linker.
  • One or more linkers may be formed by reaction of an amino acid on X with a linker already attached to Y.
  • One or more linkers may be formed by reaction of an amino acid on Y with a linker already attached to X.
  • One or more linkers may be formed by reaction of a linker already attached to X with another linker already attached to Y.
  • a bifunctional linker with two orthogonally reactive functional groups, may be coupled to X or Y, such that one remaining reactive functional group is available for subsequent coupling.
  • the linker may be the product of a bioorthogonal reaction.
  • the linker may comprise an oxime, a tetrazole, a Diels Alder adduct, a hetero Diels Alder adduct, an aromatic substitution reaction product, a nucleophilic substitution reaction product, an ester, an amide, a carbamate, an ether, a thioether, or a Michael reaction product.
  • the linker may be a cycloaddition product, a metathesis reaction product, a metal-mediated cross-coupling reaction product, a radical polymerization product, an oxidative coupling product, an acyl-transfer reaction product, or a photo click reaction product.
  • the cycloaddition may be a Huisgen-cycloaddition.
  • the cycloaddition may be a copper-free [3+2] Huisgen-cycloaddition.
  • the cycloaddition may be a Diels-Alder reaction.
  • the cycloaddition may be a hetero Diels-Alder reaction.
  • the linker may be the product of an enzyme-mediated reaction.
  • the linker may be a product of a transglutaminase-mediated reaction.
  • the linker may comprise a disulfide bridge that connects two cysteine residues, such as ThioBridgeTM technology by PolyTherics.
  • the linker may comprise a maleimide bridge that connects two amino acid residues.
  • the linker may comprise a maleimide bridge that connects two cysteine residues.
  • Each of the one or more linkers may comprise one or more ethylene glycols.
  • Each of the one or more linkers may comprise at least one reactive functional group selected from alkoxy-amine, hydrazine, aryl/alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, and disulfide.
  • the alkene may be selected from norbornene, trans-cyclooctene, and cyclopropene.
  • Each of the one or more linkers may comprise at least one alkoxy amine.
  • Each of the one or more linkers may comprise at least one azide.
  • Each of the one or more linkers may comprise at least one cyclooctyne.
  • Each of the one or more linkers may comprise at least one tetrazine.
  • the linker may couple with one or more natural amino acids on X or Y.
  • the linker may couple with one or more unnatural amino acids on X or Y.
  • the linker may couple with an amino acid which is the product of site-specific mutagenesis.
  • the linker may couple with a cysteine which is the product of site-specific mutagenesis.
  • the linker (e.g., substituted maleimide) may couple with a cysteine which is the product of site-specific mutagenesis, as well as a native cysteine residue.
  • Two linkers, each with complementary reactive functional groups, may couple with one another.
  • the one or more linkers may comprise a cleavable linker.
  • the one or more linkers may comprise a non-cleavable linker.
  • the one or more linkers may comprise a flexible linker.
  • the one or more linkers may comprise an inflexible linker.
  • the one or more linkers may comprise an alkoxy-amine, azide group and/or cyclooctyne group at one or more termini.
  • the one or more linkers may comprise an alkoxy-amine at one terminus and an azide group at the other terminus.
  • the one or more linkers may comprise an alkoxy-amine at one terminus and a cyclooctyne group at the other terminus.
  • the one or more linkers may be coupled to X, Y, or a combination thereof.
  • the one or more linkers may be coupled to X and/or Y to form one or more intermediates of the Formula III: L1′-X, Formula IIIA: X-L1′, Formula IV: L2′-Y or Formula IVA: Y-L2′.
  • the one or more linkers may be coupled to X and/or Y to form X-L1′, Y-L2′, L1′-X or L2′-Y.
  • X-L1′ may be coupled to Y.
  • X-L1′ may be coupled to L2′-Y.
  • X-L1′ may be coupled to Y.
  • X may be coupled to L2′-Y.
  • Y-L2′ may be coupled to L1′-X.
  • Y-L2′ may be coupled to X.
  • Y may be coupled to X-L1′.
  • the one or more linkers may be coupled to X and/or Y by oxime formation.
  • the one or more linkers may be coupled to X and/or Y by a cyclooctyne, cyclopropene, arly/alkyl azides, trans-cyclooctene, norborene, tetrazine bond, or a combination thereof.
  • the one or more linkers may be coupled to X and/or Y by a covalent bond, non-covalent bond, ionic bond, or a combination thereof.
  • the two or more linkers may be linked.
  • the two or more linkers may be linked through one or more copper-free reactions.
  • the two or more linkers may be linked through one or more cycloadditions.
  • the two or more linkers may be linked through one or more Huisgen-cycloadditions.
  • the two or more linkers may be linked through one or more copper-free [3+2] Huisgen-cycloadditions.
  • the two or more linkers may be linked through one or more copper-containing reactions.
  • the two or more linkers may be linked through one or more Diels Alder reactions.
  • the two or more linkers may be linked through one or more hetero Diels Alder reactions.
  • the linker may possess a length that is sufficiently long to allow the anti-CD3 antibody or antibody fragment and the second antibody or antibody fragment to be linked without steric hindrance from one another and sufficiently short to retain the intended activity of the antibody.
  • the intended activity of the antibody may be to bring an effector cell and a target cell within a proximity sufficient to allow the targeting cell to have an effect on the target cell.
  • the one or more linkers may be sufficiently hydrophilic that it does not cause instability of the antibody.
  • the one or more linkers may be sufficiently hydrophilic that it does not cause the antibody to be insoluble.
  • the one or more linkers may be sufficiently stable.
  • the one or more linkers may be sufficiently stable in vivo (e.g. it is not cleaved by serum, enzymes, etc.).
  • the one or more linkers may be between about 1 angstroms ( ⁇ ) to about 120 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 5 angstroms ( ⁇ ) to about 105 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 10 angstroms ( ⁇ ) to about 100 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 10 angstroms ( ⁇ ) to about 90 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 10 angstroms ( ⁇ ) to about 80 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 10 angstroms ( ⁇ ) to about 70 angstroms ( ⁇ ) in length.
  • the one or more linkers may be between about 15 angstroms ( ⁇ ) to about 45 angstroms ( ⁇ ) in length.
  • the one or more linkers may be equal to or greater than about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 27, 30 or more angstroms in length.
  • the one or more linkers may be equal to or greater than about 10 angstroms in length.
  • the one or more linkers may be equal to or greater than about 15 angstroms in length.
  • the one or more linkers may be equal to or greater than about 20 angstroms in length.
  • the one or more linkers may be equal to or less than about 110, 100, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30 or fewer angstroms in length.
  • the one or more linkers may be equal to or less than about 100 angstroms in length.
  • the one or more linkers may be equal to or less than about 80 angstroms in length.
  • the one or more linkers may be equal to or less than about 60 angstroms in length.
  • the one or more linkers may be equal to or less than about 40 angstroms in length.
  • the total length of the linkers may be between about 1 angstroms ( ⁇ ) to about 120 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 5 angstroms ( ⁇ ) to about 105 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 10 angstroms ( ⁇ ) to about 100 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 10 angstroms ( ⁇ ) to about 90 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 10 angstroms ( ⁇ ) to about 80 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 10 angstroms ( ⁇ ) to about 70 angstroms ( ⁇ ).
  • the total length of the linkers may be between about 15 angstroms ( ⁇ ) to about 45 angstroms ( ⁇ ).
  • the total length of the linkers may be equal to or greater than about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 27, 30 or more angstroms.
  • the total length of the linkers may be equal to or greater than about 10 angstroms.
  • the total length of the linkers may be equal to or greater than about 15 angstroms.
  • the total length of the linkers may be equal to or greater than about 20 angstroms.
  • the total length of the linkers may be equal to or less than about 110, 100, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30 or fewer angstroms.
  • the total length of the linkers may be equal to or less than about 100 angstroms.
  • the total length of the linkers may be equal to or less than about 80 angstroms.
  • the total length of the linkers may be equal to or less than about 60 angstroms.
  • the total length of the linkers may be equal to or less than about 40 angstroms.
  • the bispecific antibodies disclosed herein may comprise one or more unnatural amino acids.
  • the terms “unnatural amino acid” and “non-natural amino acid” may be used interchangeably and may refer to non-proteinogenic amino acids that either occur naturally or are chemically synthesized.
  • the bispecific antibodies of Formulas I, IA, II, and/or HA disclosed herein may comprise X, wherein X comprises one or more unnatural amino acids.
  • the bispecific antibodies of Formulas I, IA, II, and/or IIA disclosed herein may comprise X, wherein X does not comprise an unnatural amino acid.
  • the bispecific antibodies of Formulas I, IA, II, and/or IIA disclosed herein may comprise Y, wherein Y comprises one or more unnatural amino acids.
  • the bispecific antibodies of Formulas I, IA, II, and/or HA disclosed herein may comprise Y, wherein Y does not comprise an unnatural amino acid.
  • the bispecific antibodies of Formulas I, IA, II, and/or HA disclosed herein may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more unnatural amino acids.
  • the antibodies disclosed herein may comprise at least one antibody or antibody fragment that comprises one or more unnatural amino acids.
  • the antibodies disclosed herein may comprise at least two antibody or antibody fragments that independently comprise at least one unnatural amino acid.
  • the one or more unnatural amino acids may be incorporated into a bispecific antibody (e.g., antibody of Formula I, IA, II, and IIA); intermediate (e.g., intermediate of Formula III, IIIA, IV, IVA); X antibody or antibody fragment; Y antibody or antibody fragment; or a combination thereof.
  • the one or more unnatural amino acids may be site-specifically incorporated into an antibody (e.g., antibody of Formula I, IA, II, and IIA); intermediate (e.g., intermediate of Formula III, IIIA, IV, IVA); X antibody or antibody fragment; Y antibody or antibody fragment; or a combination thereof.
  • the one or more unnatural amino acids may be incorporated into an antibody fragment of an antibody (e.g., antibody of Formula I, IA, II, and HA); intermediate (e.g., intermediate of Formula III, IIIA, IV, IVA); X antibody or antibody fragment; Y antibody or antibody fragment; or a combination thereof.
  • the one or more unnatural amino acids may be site-specifically incorporated into an antibody fragment of an antibody (e.g., antibody of Formula I, IA, II, and HA); intermediate (e.g., intermediate of Formula III, IIIA, IV, IVA); X antibody or antibody fragment; Y antibody or antibody fragment; or a combination thereof.
  • the one or more unnatural amino acids may be incorporated into a heavy chain, light chain, variable region, constant region, Fab fragment of an antibody (e.g., antibody of Formula I, IA, II, and HA); intermediate (e.g., intermediate of Formula III, IIIA, IV, IVA); X antibody or antibody fragment; Y antibody or antibody fragment; or a combination thereof.
  • an antibody e.g., antibody of Formula I, IA, II, and HA
  • intermediate e.g., intermediate of Formula III, IIIA, IV, IVA
  • X antibody or antibody fragment e.g., Y antibody or antibody fragment
  • Y antibody or antibody fragment e.g., Y antibody or antibody fragment
  • the one or more unnatural amino acids may be encoded by a codon that does not code for one of the twenty natural amino acids.
  • the one or more unnatural amino acids may be encoded by a nonsense codon (stop codon).
  • the stop codon may be an amber codon.
  • the amber codon may comprise a UAG sequence.
  • the stop codon may be an ochre codon.
  • the ochre codon may comprise a UAA sequence.
  • the stop codon may be an opal or umber codon.
  • the opal or umber codon may comprise a UGA sequence.
  • the one or more unnatural amino acids may be encoded by a four-base codon.
  • the one or more unnatural amino acids may be p-acetylphenylalanine (pAcF or pAcPhe).
  • the one or more unnatural amino cids may be p-fluorophenylalanine (pFPhe).
  • the one or more unnatural amino acids may be selected from the group comprising p-azidophenylalanine (pAzF), p-benzoylphenylalanine (pBpF), p-propargyloxyphenylalanine (pPrF), p-iodophenylalanine (pIF), p-cyanophenylalanine (pCNF), p-carboxylmethylphenylalanine (pCmF), 3-(2-naphthyl)alanine (NapA), p-boronophenylalanine (pBoF), o-nitrophenylalanine (oNiF), (8-hydroxyquinolin-3-yl)alanine
  • the one or more unnatural amino acids may be ⁇ -amino acids ( ⁇ 3 and ( ⁇ 2), homo-amino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, N-methyl amino acids, or a combination thereof.
  • unnatural amino acids include, but are not limited to, 1) various substituted tyrosine and phenylalanine analogues such as O-methyl-L-tyrosine, p-amino-L-phenylalanine, 3-nitro-L-tyrosine, p-nitro-L-phenylalanine, m-methoxy-L-phenylalanine and p-isopropyl-L-phenylalanine; 2) amino acids with aryl azide and benzophenone groups that may be photo-cross-linked; 3) amino acids that have unique chemical reactivity including acetyl-L-phenylalanine and m-acetyl-L-phenylalanine, O-allyl-L-tyrosine, O-(2-propynyl)-L-tyrosine, p-ethylthiocarbonyl-L-phenylalanine and p-(3-oxobutanoyl)-L-pheny
  • the one or more unnatural amino acids may comprise at least one oxime, carbonyl, dicarbonyl, hydroxylamine group or a combination thereof.
  • the one or more unnatural amino acids may comprise at least one carbonyl, dicarbonyl, alkoxy-amine, hydrazine, acyclic alkene, acyclic alkyne, cyclooctyne, aryl/alkyl azide, norbornene, cyclopropene, trans-cyclooctene, or tetrazine functional group or a combination thereof.
  • the one or more unnatural amino acids may be incorporated into X and/or Y by methods known in the art.
  • Cell-based or cell-free systems may be used to alter the genetic sequence of X and/or Y, thereby producing X and/or Y with one or more unnatural amino acids.
  • Auxotrophic strains may be used in place of engineered tRNA and synthetase.
  • the one or more unnatural amino acids may be produced through selective reaction of one or more natural amino acids.
  • the selective reaction may be mediated by one or more enzymes.
  • the selective reaction of one or more cysteines with formylglycine generating enzyme (FGE) may produce one or more formylglycines.
  • FGE formylglycine generating enzyme
  • the one or more unnatural amino acids may take part in a chemical reaction to form a linker.
  • the chemical reaction to form the linker may be a bioorthogonal reaction.
  • the chemical reaction to form the linker may be click chemistry.
  • compositions comprising one or more bispecific antibodies disclosed herein.
  • the compositions may comprise a bispecific antibody comprising an anti-CD3 antibody or anti-CD3 antibody fragment and a second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment is site-specifically connected to the second antibody or antibody fragment.
  • the compositions may comprise a bispecific antibody comprising (a) an anti-CD3 antibody or anti-CD3 antibody fragment; (b) a second antibody or antibody fragment; and (c) one or more linkers, wherein the one or more linkers links the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment, wherein the anti-CD3 antibody or anti-CD3 antibody fragment is site-specifically linked to the second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the composition may further comprise one or more pharmaceutically acceptable excipients.
  • the composition may further comprise one or more solvents or diluents.
  • the composition may comprise a bispecific antibody of Formula I: X-L1-Y, wherein (i) X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; (ii) L1 comprises a linker; and (iii) Y comprises a second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the composition may further comprise one or more pharmaceutically acceptable excipients.
  • the composition may further comprise one or more solvents or diluents.
  • the composition may comprise a bispecific antibody of Formula IA: Y-L1-X, wherein (i) X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; (ii) L1 comprises a linker; and (iii) Y comprises a second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the composition may further comprise one or more pharmaceutically acceptable excipients.
  • the composition may further comprise one or more solvents or diluents.
  • the composition may comprise a bispecific antibody of Formula II: X-L1-L2-Y, wherein (i) X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; (ii) L1 and L2 comprise a linker; and (iii) Y comprises a second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the composition may further comprise one or more pharmaceutically acceptable excipients.
  • the composition may further comprise one or more solvents or diluents.
  • the composition may comprise a bispecific antibody of Formula IIA: Y-L2-L1-X, wherein (i) X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; (ii) L1 and L2 comprise a linker; and (iii) Y comprises a second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids.
  • the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the anti-CD3 antibody or anti-CD3 antibody fragment and the second antibody or antibody fragment may comprise one or more unnatural amino acids.
  • the composition may further comprise one or more pharmaceutically acceptable excipients.
  • the composition may further comprise one or more solvents or diluents.
  • pharmaceutically acceptable refers to a material that does not abrogate the biological activity or properties of the agents described herein, and is relatively nontoxic (i.e., the toxicity of the material significantly outweighs the benefit of the material).
  • a pharmaceutically acceptable material may be administered to an individual without causing significant undesirable biological effects or significantly interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • compositions herein may be formulated using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active agents into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • a summary of pharmaceutical compositions is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins, 1999).
  • a pharmaceutical composition disclosed herein may further comprise a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s).
  • the pharmaceutical compositions may include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers.
  • the pharmaceutical compositions also contain other therapeutically valuable substances.
  • a pharmaceutical composition disclosed herein may be administered to a subject by any suitable administration route, including but not limited to, parenteral (intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular, intrathecal, intravitreal, infusion, or local), topical, oral, or nasal administration.
  • a pharmaceutical composition disclosed herein may be administered to a subject by an intranasal administration.
  • a pharmaceutical composition disclosed herein may be administered to a subject by a microneedle device.
  • the microneedle device may be used to deliver a low dosage of the pharmaceutical composition due to the relatively high potency or efficacy of the antibody.
  • the microneedle device may be a microneedle device as described in U.S. Pat. No. 7,416,541, Peters et al., Pharm Res 29:1618-26 (2012), and Daddona et al., Pharm Res. 28:159-65 (2011).
  • Formulations suitable for intramuscular, subcutaneous, peritumoral, or intravenous injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Formulations suitable for subcutaneous injection also contain optional additives such as preserving, wetting, emulsifying, and dispensing agents.
  • an active agent may be optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • Parenteral injections optionally involve bolus injection or continuous infusion.
  • Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative.
  • the pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical formulations for parenteral administration include aqueous solutions of an active agent in water soluble form. Additionally, suspensions are optionally prepared as appropriate oily injection suspensions.
  • the pharmaceutical composition described herein may be in unit dosage forms suitable for single administration of precise dosages.
  • the formulation may divided into unit doses containing appropriate quantities of an active agent disclosed herein.
  • the unit dosage may be in the form of a package containing discrete quantities of the formulation.
  • Non-limiting examples are packaged tablets or capsules, and powders in vials or ampoules.
  • Aqueous suspension compositions may be packaged in single-dose non-reclosable containers.
  • multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
  • formulations for parenteral injection are presented in unit dosage form, which include, but are not limited to ampoules, or in multi dose containers, with an added preservative.
  • Disclosed herein are methods of producing bispecific antibodies comprising connecting an anti-CD3 antibody or anti-CD3 antibody fragment and a second antibody or antibody fragment site-specifically.
  • methods of producing the antibody of Formula I: X-L1-Y or Formula IA: Y-L1-X comprising coupling L1′′ to X to produce an intermediate of Formula III: X-L1′ or Formula IIIA: L1′-X, wherein X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; and coupling the intermediate to Y; wherein Y comprises at least a portion of a second antibody or antibody fragment; thereby producing the antibody of Formula I or IA.
  • Y-L1-X a method of producing bispecific antibodies of Formula I: X-L1-Y or Formula IA: Y-L1-X, comprising coupling L1′′ to Y to produce an intermediate of Formula IV: Y-L1′ or Formula IVA: L1′-Y, wherein Y comprises at least a portion of a second antibody or antibody fragment; and coupling the intermediate to X, wherein X comprises an anti-CD3 antibody or anti-CD3 antibody fragment, thereby producing the antibody of Formula I or IA.
  • the method may further comprise incorporating one or more unnatural amino acids into X and/or Y.
  • the method may further comprise incorporating one or more unnatural amino acids into X and/or Y site-specifically.
  • Y-L1-L2-X a) coupling L1′′ to X to produce a first intermediate of Formula III: X-L1′ or Formula IIIA: L1′-X, wherein X comprises an anti-CD3 antibody or anti-CD3 antibody fragment; (b) coupling L2′′ to Y to produce a second intermediate of Formula IV: L2′-Y or Formula IVA: Y-L2′, wherein Y comprises at least a portion of a second antibody or antibody fragment; and (c) linking the first intermediate to the second intermediate, thereby producing the antibody of Formula II or IIA.
  • the method may further comprise incorporating one or more unnatural amino acids into X and/or Y.
  • the method may further comprise incorporating one or more unnatural amino acids into X and/or Y site-specifically.
  • Coupling L1′′ to X may comprise coupling L1′′ to X site-specifically.
  • Coupling L2′′ to Y may comprise coupling L2′′ to Y site-specifically.
  • Coupling L1′′ to X and coupling L2′′ to Y may comprise coupling L1′′ to X site-specifically and coupling L2′′ to Y site-specifically.
  • the method may further comprise coupling L1′′/L2′′ to Y at the one or more unnatural amino acids of Y.
  • the method may further comprise coupling L1′′ to X at the one or more unnatural amino acids of Y.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise an unnatural amino acid.
  • the second antibody or antibody fragment may comprise an unnatural amino acid.
  • Coupling one or more first linkers to the anti-CD3 antibody or anti-CD3 antibody fragment to produce the first intermediate may comprise forming a stable oxime between the anti-CD3 antibody or anti-CD3 antibody fragment and the linker.
  • Coupling one or more second linkers to the second antibody or antibody fragment to produce the second intermediate may comprise forming a stable oxime between the second antibody or antibody fragment and the linker.
  • the oxime may be formed between an alkoxy-amine group of the linker and the unnatural amino acid.
  • the oxime may be formed between an alkoxy-amine group of the linker and a ketone of the unnatural amino acid.
  • the oxime may be formed between an alkoxy-amine group of the linker and a ketone of the unnatural amino acid, wherein the unnatural amino acid is p-acetylphenylalanine (pAcF).
  • pAcF p-acetylphenylalanine
  • the oxime may be between an alkoxy-amine group of the first linker and the unnatural amino acid of the anti-CD3 antibody or anti-CD3 antibody fragment.
  • the oxime may be formed between an alkoxy-amine group of the second linker and the unnatural amino acid of the second antibody.
  • the first/second linker may be a bifunctional linker.
  • the bifunctional linker may comprise an azide group.
  • the bifunctional linker may comprise a cyclooctyne group.
  • the azide group may be linked to the cyclooctyne group through a chemical reaction.
  • the chemical reaction may be a copper-free [3+2] Huisgen-cycloaddition (“Click” reaction).
  • the first/second linker may be a heterobifunctional linker.
  • the heterobifunctional linker may comprise two reactive functional groups selected from alkoxy-amine, hydrazine, aryl/alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, and disulfide.
  • the anti-CD3 antibody may not comprise an unnatural amino acid while the second antibody or antibody fragment does comprise an unnatural amino acid.
  • Coupling the one or more linkers to the anti-CD3 antibody or anti-CD3 antibody fragment may comprise forming a stable oxime between the anti-CD3 antibody or anti-CD3 antibody fragment and one or more of the first linkers to form the first intermediate.
  • the oxime may be formed between an alkoxy-amine group of the first linker and the natural amino acid of the anti-CD3 antibody or anti-CD3 antibody fragment.
  • Coupling one or more second linkers to the second antibody or antibody fragment to produce the second intermediate may comprise forming a stable oxime between the second antibody or antibody fragment and the one or more second linkers.
  • the oxime may be formed between an alkoxy-amine group of the second linker and the unnatural amino acid of the second antibody or antibody fragment.
  • the first/second linker may be a bifunctional linker.
  • the bifunctional linker may comprise an azide group.
  • the bifunctional linker may comprise a cyclooctyne group.
  • the azide group may be linked to the cyclooctyne group through a chemical reaction.
  • the chemical reaction may be a copper-free [3+2] Huisgen-cycloaddition (“Click” reaction).
  • the first/second linker may be a heterobifunctinoal linker.
  • the heterobifunctional linker may comprise two reactive functional groups selected from alkoxy-amine, hydrazine, aryl/alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, and disulfide.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise an unnatural amino acid, while the second antibody does not comprise an unnatural amino acid.
  • Coupling the one or more linkers to second antibody or antibody fragment may comprise forming a stable oxime between the second antibody or antibody fragment and one or more of the second linkers to form the second intermediate.
  • the oxime may be formed between an alkoxy-amine group of the second linker and the natural amino acid.
  • Coupling one or more first linkers to the anti-CD3 antibody or anti-CD3 antibody fragment to produce the first intermediate may comprise forming a stable oxime between the anti-CD3 antibody or antibody fragment and the one or more first linkers.
  • the oxime may be formed between an alkoxy-amine group of the first linker and the unnatural amino acid.
  • the first/second linker may be a bifunctional linker.
  • the bifunctional linker may comprise an azide group.
  • the bifunctional linker may comprise a cyclooctyne group.
  • the azide group may be linked to the cyclooctyne group through a chemical reaction.
  • the chemical reaction may be a copper-free [3+2] Huisgen-cycloaddition (“Click” reaction).
  • the first/second linker may be a heterobifunctional linker.
  • the heterobifunctional linker may comprise two reactive functional groups selected from alkoxy-amine, hydrazine, aryl/alkyl azide, alkyne, alkene, tetrazine, dichlorotriazine, tresylate, succinimidyl carbonate, benzotriazole carbonate, nitrophenyl carbonate, trichlorophenyl carbonate, carbonylimidazole, succinimidyl succinate, maleimide, vinylsulfone, haloacetamide, and disulfide.
  • Conjugating the first intermediate to the second intermediate may comprise one or more Huisgen-cycloadditions. Conjugating the first intermediate to the second intermediate may comprise one or more copper-free [3+2] Huisgen-cycloadditions. Conjugating the first intermediate to the second intermediate may comprise one or more copper-containing reactions. Conjugating the first intermediate to the second intermediate may comprise one or more Diels Alder reactions. Conjugating the first intermediate to the second intermediate may comprise one or more hetero Diels Alder reactions.
  • Conjugating the one or more of the first linkers to the one or more of the second linkers may comprise one or more Huisgen-cycloadditions. Conjugating the one or more of the first linkers to the one or more of the second linkers may comprise one or more copper-free [3+2] Huisgen-cycloadditions. Conjugating the one or more of the first linkers to the one or more of the second linkers may comprise one or more copper-containing reactions. Conjugating the one or more of the first linkers to the one or more of the second linkers may comprise one or more Diels Alder reactions. Conjugating the one or more of the first linkers to the one or more of the second linkers may comprise one or more hetero Diels Alder reactions.
  • a method of producing the bispecific antibody of Formula II: X-L1-L2-Y comprising (a) coupling L1′′ to X to produce a first intermediate of Formula IIIA: X-L1′, wherein X comprises at least a portion of an anti-CD3 antibody or anti-CD3 antibody fragment; (b) coupling L2′′ to Y to produce a second intermediate of Formula IV: L2′-Y, wherein Y comprises at least a portion of an antibody or antibody fragment; and (c) linking the first intermediate of Formula III to the second intermediate of Formula IV, thereby producing the antibody of Formula II.
  • the method may further comprise incorporating one or more unnatural amino acids into X and/or Y.
  • Incorporating one or more unnatural amino acids into an antibody or antibody fragment may comprise modifying one or more amino acid residues in an antibody or antibody fragment to produce one or more amber codons in an antibody or antibody fragment.
  • the one or more unnatural amino acids may incorporated into an antibody or antibody fragment in response to an amber codon.
  • the one or more unnatural amino acids may be site-specifically incorporated into an antibody or antibody fragment.
  • Additional methods for incorporating unnatural amino acids include, but are not limited to, methods disclosed in Chatterjee et al. (A Versatile Platform for Single- and Multiple-Unnatural Amino Acid Mutagenesis in Escherichia coli, Biochemistry, 2013), Kazane et al. ( J Am Chem Soc, 135(1):340-6, 2013), Kim et al. ( J Am Chem Soc, 134(24):9918-21, 2012), Johnson et al. ( Nat Chem Biol, 7(11):779-86, 2011) and Hutchins et al. ( J Mol Biol, 406(4):595-603, 2011).
  • the methods disclosed herein may comprise coupling one or more linkers to one or more antibodies, antibody fragments, or combinations thereof to produce one or more antibody-linker and/or antibody fragment-linker molecules.
  • the methods may comprise coupling a first linker to a first antibody or antibody fragment to produce an antibody-linker molecule or antibody fragment-linker molecule.
  • the methods may comprise coupling a second linker to a second antibody or antibody fragment to produce an antibody-linker molecule or antibody fragment-linker molecule.
  • Coupling of the one or more linkers to the antibody or antibody fragment may occur simultaneously. Coupling of the one or more linkers to the antibody or antibody fragment may occur sequentially. Coupling of the one or more linkers to the antibody or antibody fragment may occur in a single reaction volume. Coupling of the one or more linkers to the antibody or antibody fragment may occur in two or more reaction volumes.
  • Coupling one or more linkers to an antibody or antibody fragment may comprise forming one or more oximes between the linker and the antibody or antibody fragment. Coupling one or more linkers to an antibody or antibody fragment may comprise forming one or more stable bonds between linker and the antibody or antibody fragment. Coupling one or more linkers to an antibody or antibody fragment may comprise forming one or more covalent bonds between linker and the antibody or antibody fragment. Coupling one or more linkers to an antibody or antibody fragment may comprise forming one or more non-covalent bonds between linker and the antibody or antibody fragment. Coupling one or more linkers to an antibody or antibody fragment may comprise forming one or more ionic bonds between linker and the antibody or antibody fragment.
  • the methods may comprise linking the antibody, antibody fragment and/or intermediates thereof to produce a bispecific antibody comprising (a) an anti-CD3 antibody or anti-CD3 antibody fragment; (b) a second antibody or antibody fragment; and (c) one or more linkers, wherein the one or more linkers link the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment.
  • the anti-CD3 antibody or anti-CD3 antibody fragment may comprise one or more unnatural amino acids
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise conducting one or more copper-free reactions
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise conducting one or more copper-containing reactions
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise one or more cycloadditions.
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise one or more Huisgen-cycloadditions
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise one or more Diels Alder reactions.
  • Linking the anti-CD3 antibody or anti-CD3 antibody fragment to the second antibody or antibody fragment may comprise one or more Hetero Diels Alder reaction.
  • the methods may further comprise purifying the bispecific antibody comprising (a) an anti-CD3 antibody or antibody fragment comprising one or more unnatural amino acids; (b) a second antibody or antibody fragment; and (c) one or more linkers, wherein the one or more linkers link the anti-CD3 antibody or antibody fragment to the second antibody or antibody fragment.
  • the methods may further comprise purifying one or more intermediates of the antibody or antibody fragment antibody or antibody fragment (e.g., antibody-linker or antibody fragment-linker). Purifying the antibody or intermediates may comprise removal of excess linkers, non-linked antibodies or non-linked antibody fragments. Purifying the antibody or intermediates may comprise use of one or more concentrator columns, electrophoresis, filtration, centrifugation, chromatography or a combination thereof.
  • Chromatography may comprise size-exclusion chromatography. Additional chromatography methods include, but are not limited to, hydrophobic interaction chromatography, ion exchange chromatography, affinity chromatography, metal binding, immunoaffinity chromatography, and high performance liquid chromatography or high pressure liquid chromatography. Electrophoresis may comprise denaturing electrophoresis or non-denaturing electrophoresis.
  • Antibodies or intermediates may comprise one or more tags.
  • the linkers may comprise one or more tags.
  • the tags may be used to purify the antibodies or intermediates.
  • the one or more tags may be cleaved by one or more proteases. Examples of tags include, but are not limited to, polyhistidine, FLAG, HA, c-myc, V5, chitin binding protein (CBP), maltose binding protein (MBP), and glutathione-S-transferase (GST).
  • the methods may further comprise lyophilization or ultracentrifugation of the antibodies or intermediates.
  • the purity of the bispecific antibody may be equal to or greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.
  • the purity of the antibody may be equal to or greater than 85%.
  • the purity of the antibody may be equal to or greater than 90%.
  • the purity of the antibody may be equal to or greater than 95%.
  • the purity of the antibody may be equal to or greater than 97%.
  • the purity of the intermediate may be equal to or greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.
  • the purity of the antibody may be equal to or greater than 85%.
  • the purity of the antibody may be equal to or greater than 90%.
  • the purity of the antibody may be equal to or greater than 95%.
  • the purity of the antibody may be equal to or greater than 97%.
  • the homogeneity of the bispecific antibody may be equal to or greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.
  • the homogeneity of the antibody may be equal to or greater than 85%.
  • the homogeneity of the antibody may be equal to or greater than 90%.
  • the homogeneity of the antibody may be equal to or greater than 95%.
  • the homogeneity of the antibody may be equal to or greater than 97%.
  • the homogeneity of the intermediate may be equal to or greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.
  • the homogeneity of the antibody may be equal to or greater than 85%.
  • the homogeneity of the antibody may be equal to or greater than 90%.
  • the homogeneity of the antibody may be equal to or greater than 95%.
  • the homogeneity of the antibody may be equal to or greater than 97%.
  • the bispecific antibodies disclosed herein may bind to one or more receptors, co-receptors, antigens, or cell markers on one or more cells.
  • the bispecific antibodies disclosed herein may comprise (a) an anti-CD3 antibody or antibody fragment and (b) a second antibody or antibody fragment, wherein (i) the anti-CD3 antibody or antibody fragment binds to or interacts with CD3 on a first cell; (ii) the second antibody or antibody fragment binds to or interacts with a receptor, co-receptor, antigen or cell marker on a second cell; or (iii) a combination of (i) and (ii), and wherein (iv) the anti-CD3 antibody or antibody fragment comprises one or more unnatural amino acids; (v) the second antibody or antibody fragment comprises one or more unnatural amino acids; or (vi) a combination of (iv) and (v).
  • the first cell may be an effector cell.
  • the effector cell may be a T cell.
  • the second cell may be a target cell.
  • the target cell may be a cancerous cell.
  • the first cell and the second cell may be the same type of cell.
  • the first cell and the second cell may be different cell types. Alternatively, the first cell and the second cell may be the same cell.
  • the one or more cells may be hematopoietic cells.
  • Hematopoietic cells include, but are not limited to, basophilic myelocytes, basophils, B-cells, burst forming unit erythroid (BFU-E), burst forming unit megakaryocytes (BFU-Mk), colony forming unit basophils (CFU-Bas), colony forming unit erythroid (CFU-E), colonly forming unit eosinophils (CFU-Eo), colony forming unit granulocytes (CFU-G), colony forming unit granulocyte erythrocyte monocyte macrophage (CFU-GEMM), colony forming unit granulocyte maccrophage (CFU-GM), colony forming unite megakaryocyte (CFU-Mk, CFU-MEG), common dendritic progenitor, common lymphoid progenitor cells, common myeloerythroid progenitors, common my
  • BFU-E or CFU-E may refer to erythroid precursor cells that may differentiate into erythrocytes.
  • CFU-E cells may be more developed than BFU-E cells.
  • CFU-Eo may refer to developmental type of blood-forming cells that may develop into eosinophils.
  • CFU-G may refer to a developmental type of blood-forming cells that may be a precursor of granulocytes.
  • CFU-GEMM may refer to a pluripotent type of precursor cell in the lineage of blood-forming cells that may differentiate into granuclocytes, erythrocytes, monocytes and/or macrophages.
  • CFU-GM may refer to a pluropotent type of precursor cell in the lineage of blood-forming cells that may differentiate into granuloctyes and/or macrophages.
  • BFU-Mk, CFU-Mk or CFU-MEG may refer to precursor cells that may differentiate into megakaryocytes.
  • CFU-Mk or CFU-MEG cells may be more developed than BFU-Mk cells.
  • the one or more cells may be from an organ or tissue.
  • the organ may be a gland organ.
  • the organ may be an organ of the digestive or endocrine system.
  • the organ may be both an endocrine gland and a digestive organ.
  • the organ may be derived from endoderm, ectoderm, primitive endoderm, or mesoderm.
  • the organ may be an adrenal gland.
  • the adrenal gland comprises chromaffin cells or ganglion cells.
  • the organ is an appendix, bladder, or brain.
  • the brain comprises neurons (e.g., nerve cells) or glial cells.
  • Glial cells include, but are not limited to, astrocytes, oligodendrocytes, and ependymal cells.
  • the organ is an ear, esophagus, eye, or gallbladder.
  • the gallbladder comprises cholecystocytes.
  • the organ may be a kidney.
  • the kidney may comprise a kidney glomerulus parietal cell, kidney glomerululs podocyte, kidney proximal tubule brush border cell, Loop of Henle thin segment cell, thick ascending limb cell, kidney distal tubule cell, kidney collecting ductal cell, or interstitial kidney cell.
  • the organ is a large intestine and the large intestine may comprise enterocytes, goblet cells, caveolated tuft cells, enteroendocrine cells, or ganglion neurons.
  • the organ may be a liver.
  • the liver may comprise parenchymal or non-parenchymal cells.
  • parenchymal cells comprise hepatocytes.
  • Non-parenchymal cells include, but are not limited to, sinusoidal endothelial cells, kupffer cells and hepatic stellate cells.
  • the organ is a lung, mouth, nose, parathyroid gland, pineal gland, pituitary gland, skin, small intestine, stomach, spleen, thymus, thyroid gland, trachea, uterus, or vermiform appendix.
  • the organ may be a heart.
  • the heart comprises cardiomyocytes.
  • the organ is a muscle (e.g., heart muscle, skeletal muscle, smooth muscle, etc.). The muscle may comprise myocytes.
  • the cells are from a tissue.
  • the tissue may be a connective tissue, epithelial tissue, muscular tissue, or nervous tissue.
  • the tissue is a bone, tendon (both referred to as musculoskeletal grafts), cornea, skin, heart valve, or vein.
  • Connective tissue may be a fibrous tissue and is often found throughout the body.
  • connective tissues include, but are not limited to, connective tissue, fat tissue, dense fibrous tissue, cartilage, bone, blood, and lymph.
  • connective tissue has three main components: cells, fibers, and extracellular matrix, which may be embedded in the body fluids. Fibroblasts are often the cells responsible for the production of connective tissue. The interaction of the fibers, the extracellular matrix and the water, together, may form the pliable connective tissue as a whole.
  • Connective tissue may make up a variety of physical structures including tendons and the connective framework of fibers in muscles, capsules and ligaments around joints, cartilage, bone, adipose tissue, blood and lymphatic tissue.
  • Connective tissue may be classified into three subtypes: embryonic CT, proper CT, and special CT.
  • the proper CT subtype may include dense regular CT, dense irregular CT, and loose CT.
  • the special CT subtype may include cartilage, bone, adipose tissue, blood, hematopoietic tissue and lymphatic tissue.
  • connective tissues have distinct functions, characteristics, and compositions.
  • the functions of connective tissue may include storage of energy, protection of organs, providing structural framework for the body, and connection of body tissues.
  • the connective tissue may be characterized by cells that are spread through an extracellular fluid.
  • the connective tissue may comprise a ground substance, which is often a clear, colorless, and viscous fluid containing glycosaminoglycans and proteoglycans.
  • the ground substance may fix the bodywater and the collagen fibers in the intercellular spaces. Ground substance may also slow the spread of pathogens.
  • the connective tissue may be fibrous and the fibrous tissue may comprise distinct compositions and be localized to specific areas of the body.
  • collagenous fibers often contain alpha polypeptide chains and may be primarily localized to a tendon, ligament, skin, cornea, cartilage, bone, blood vessels, gut, and intervertebral disc.
  • elastic fibers may comprise elastic microfibrill and elastin and may be primarily localized to an extracellular matrix.
  • Reticular fibers are another example of fibrous tissue and may be localized to the liver, bone marrow, or lymphatic organs.
  • connective tissues are fibrous.
  • non-fibrous connective tissues are adipose tissue and blood.
  • Adipose tissue may provide a “mechanical cushioning” to our body.
  • groups of adipose cells may be kept together by collagen fibers and collagen sheets in order to keep fat tissue under compression in place (for example the sole of the foot).
  • Epithelia are tissues that may consist of closely apposed cells without intervening intercellular substances. Epithelia are often avascular, but epithelia may “grow” on an underlying layer of vascular connective tissue. The connective tissue and the epithelium may be separated by a basement membrane. Epithelium may cover all free surfaces of the body. Epithelium may also line the large internal body cavities, where it is termed mesothelium. Furthermore, the internal surfaces of blood and lymph vessels may be lined by epithelium, here called endothelium. Epithelia are often classified on the basis of the number of cell layers and the shape of the cells in the surface layer. If there is only one layer of cells in the epithelium, it is designated simple. If there are two or more layers of cells, it is termed stratified. Cells in the surface layer may be described according to their height as squamous (scale- or plate-like), cuboidal or columnar.
  • pseudostratified columnar may function to remove dust and particles from airways and may have cilia.
  • the pseudostratified columnar may line the respiratory passageways.
  • the simple columnar may be involved in absorption and often line the uterus and most organs of the digestive tract.
  • the simple cuboidal may be involved in secretion and absorption and may be localized to glands, kidney tubules, and ovaries.
  • the simple squamous may play a role in diffusion and filtration and may be localized to lungs, walls of capillaries and vessels.
  • the stratified squamous may protect underlying cells and is often localized to the skin, throat, vagina, and mouth.
  • the stratified cuboidal may be involved in protection and may line ducts of the mammary glands, sweat glands, and pancreas.
  • the stratified columnar may be involved in protection and secretion and may be localized to the male urethra and vas deferens, and parts of the pharynx.
  • Muscular tissue is often a contractile tissue and may be derived from the mesodermal layer of embryonic germ cells. Muscle cells may contain contractile filaments that move past each other and change the size of the cell. They are classified as skeletal, cardiac, or smooth muscles. Skeletal muscle or “voluntary muscle” may be anchored by tendons (or by aponeuroses at a few places) to bone and may be used to effect skeletal movement such as locomotion and in maintaining posture.
  • Smooth muscle or “involuntary muscle” is often found within the walls of organs and structures such as the esophagus, stomach, intestines, bronchi, uterus, urethra, bladder, blood vessels, and the arrector pili in the skin (in which it controls erection of body hair).
  • Cardiac muscle is also an “involuntary muscle” but may be more structurally similar to skeletal muscle, and is often found in the heart.
  • Cardiac and skeletal muscles are often “striated” in that they contain sarcomeres and are packed into highly regular arrangements of bundles. While skeletal muscles may be arranged in regular, parallel bundles, cardiac muscle often connects at branching, irregular angles (called intercalated discs). Striated muscle may contract and relax in short, intense bursts, whereas smooth muscle may sustain longer or even near-permanent contractions.
  • Skeletal muscle may be divided into several subtypes.
  • Type I slow oxidative, slow twitch, or “red” muscle is often dense with capillaries and may be rich in mitochondria and myoglobin, giving the muscle tissue its characteristic red color. It may carry more oxygen and sustain aerobic activity.
  • Type II fast twitch muscle, has three major kinds, Type IIa, Type IIx, and Type IIb.
  • Type IIa is often aerobic and may be rich in mitochondria and capillaries and may appear red.
  • Type IIx also known as type IId
  • Type IIb which may be anaerobic, glycolytic, “white” muscle that is often even less dense in mitochondria and myoglobin.
  • Nervous tissue is one of four major classes of tissue. Nervous tissue is often the main component of the nervous system, the brain, spinal cord, and nerves, which may regulate and control body functions. Nervous tissue is often composed of neurons and the neuroglia cells. Neurons may transmit impulses. Neuroglial cells may assist in propagation of the nerve impulse as well as provide nutrients to the neuron. Nervous tissue is often made of nerve cells that may come in many varieties, all of which may be distinctly characteristized by the axon or long stem like part of the cell that sends action potential signals to the next cell.
  • Nervous tissue may react to stimuli and may conduct impulses to various organs in the body which often bring about a response to the stimulus.
  • Nerve tissue (as in the brain, spinal cord and peripheral nerves that branch throughout the body) are often made up of specialized nerve cells called neurons. Neurons are easily stimulated and transmit impulses very rapidly.
  • a nerve often comprises many nerve cell fibers (neurons) bound together by connective tissue.
  • a sheath of dense connective tissue, the epineurium may surround the nerve. This sheath penetrates the nerve to form the perineurium which surrounds bundles of nerve fibers. Blood vessels of various sizes may be seen in the epineurium.
  • the endoneurium which consists of a thin layer of loose connective tissue, surrounds the individual nerve fibers.
  • the cell body may be enclosed by a cell (plasma) membrane and may have a central nucleus. Granules called Nissl bodies are often found in the cytoplasm of the cell body. Within the cell body, extremely fine neurofibrils may extend from the dendrites into the axon. The axon is often surrounded by the myelin sheath, which forms a whitish, non-cellular, fatty layer around the axon. Outside the myelin sheath may be a cellular layer called the neurilemma or sheath of Schwann cells. The myelin sheath together with the neurilemma is also known as the medullary sheath. This medullary sheath may be interrupted at intervals by the nodes of Ranvier.
  • the cells may also comprise hair follicles, hair cells, ear hair cells, ear hair stem cells, or cochlear cells. Hair cells are often the sensory receptors of both the auditory system and the vestibular system.
  • the auditory hair cells may be located within the organ of Corti on a thin basilar membrane in the cochlea of the inner ear.
  • Cochlear hair cells may come in two anatomically and functionally distinct types: the outer and inner hair cells.
  • the cells described herein may be diseased, infected, mutated or genetically modified.
  • the one or more cells may be a pathogenic cell.
  • Pathogenic cells include, but are not limited to, bacteria, viruses, fungi, and protozoans.
  • pathogens may include, but are not limited to, the bacteria, viruses, fungi, and protozoans disclosed herein.
  • the bispecific antibodies disclosed herein may bind to one or more receptors, co-receptors, antigens, or cell markers on one or more cells.
  • the bispecific antibodies disclosed herein may comprise (a) a anti-CD3 antibody or antibody fragment and (b) a second antibody or antibody fragment, wherein (i) the anti-CD3 antibody or antibody fragment binds to or interacts with CD3 on a first cell; (ii) the second antibody or antibody fragment binds to or interacts with a receptor, co-receptor, antigen or cell marker on a second cell; or (iii) a combination of (i) and (ii), and wherein (iv) the anti-CD3 antibody or antibody fragment comprises one or more unnatural amino acids; (v) the second antibody or antibody fragment comprises one or more unnatural amino acids; or (vi) a combination of (iv) and (v).
  • the first cell and the second cell may be the same type of cell.
  • the first cell and the second cell may be different cell types.
  • X may comprise an antibody or antibody fragment that binds to CD3 or a portion thereof.
  • Y comprises an antibody or antibody fragment that may bind to a receptor, co-receptor, antigen, transmembrane protein or cell marker.
  • receptors, co-receptors, antigens or cell markers may include, but are not limited to, a receptor, co-receptor, antigen or cell marker on a hematopoietic cell, tissue cell, epithelial cell, mesothelial cell, dermal cell, endothelial cell, dendritic cell, vascular cell, stromal cell, neuron, cancer cell, bacteria, fungus, or virus.
  • the receptors, co-receptors, antigens or cell markers may be selected from the group comprising CD19, CD20, CD22, CD25, CD30, CD40, CD56, CD64, CD70, CD74, CD79, CD105, CD138, CD174, CD205, CD227, CD326, CD340, MUC16, GPNMB, PSMA, Cripto, ED-8, TMEFF2, EphB2, EphA2, FAP, av integrin, mesothelin, EGFR, TAG-72, GD2, CAIX, and 5T4.
  • An antigen may evoke the production of one or more antibodies.
  • An antigen may refer to a molecule or molecular fragment that may be bound by a major histocompatiblity complex (MHC) and presented to a T-cell receptor.
  • MHC major histocompatiblity complex
  • the term “antigen” may also refer to an immunogen.
  • An immunogen may provoke an adaptive immune response if injected on its own into a subject.
  • An immunogen may induce an immune response by itself.
  • An antigen may also refer to a hapten.
  • a hapten may be a small molecule. Generally, a hapten may induce an immune repsonse when attached to a larger carrier molecule, such as a protein.
  • Antigens may be proteins or polysaccharides.
  • Antigens may comprise parts (e.g., coats, capsules, cell walls, flagella, fimbrae, and toxins) of bacteria, viruses, and other microorganisms. Lipids and nucleic acids may be antigenic when combined with proteins and polysaccharides. Antigens may include superantigens, T-dependent antigens and T-independent antigens.
  • Antigens may be exogenous antigens or endogeneous antigens.
  • Exogeneous antigens are typically antigens that have entered the body from the outside, for example by inhalation, ingestion, or injection. Some antigens may start out as exogenous antigens, and later become endogenous (for example, intracellular viruses). Intracellular antigens may be released back into circulation upon the destruction of the infected cell, again.
  • Endogenous antigens may be antigens that have been generated within previously-normal cells as a result of normal cell metabolism, or because of viral or intracellular bacterial infection.
  • Antigens may also include autoantigens.
  • An autoantigen may be a normal protein or complex of proteins (and sometimes DNA or RNA) that is recognized by the immune system of patients suffering from a specific autoimmune disease. These antigens should, under normal conditions, not be the target of the immune system, but, due to mainly genetic and environmental factors, the normal immunological tolerance for such an antigen has been lost in these patients.
  • Antigens may include tumor antigens.
  • Tumor antigens or neoantigens may be antigens that are presented by MHC I or MHC II molecules on the surface of tumor cells. These antigens may sometimes be presented by tumor cells and never by the normal ones. In this case, they are called tumor-specific antigens (TSAs) and, in general, result from a tumor-specific mutation. More common are antigens that are presented by tumor cells and normal cells, and they are called tumor-associated antigens (TAAs). Cytotoxic T lymphocytes that recognize these antigens may be able to destroy the tumor cells before they proliferate or metastasize.
  • Tumor antigens may also be on the surface of the tumor in the form of, for example, a mutated receptor, in which case they may be recognized by B cells.
  • the condition or disease may comprise a cancer.
  • the cancer may be selected from a prostate cancer, a myeloid leukemia, an epithelial cancer, an ovarian cancer, a cervical cancer, a breast cancer, a lung cancer, a kidney cancer, a colorectal cancer, a brain cancer, a thyroid cancer, an astrocytoma, a pancreatic cancer, an endometrial cancer, a neuroendocrine cancer, a gastroenteropancreatic tumor, a non-Hodgkin's lymphoma, a skin cancer, a gastric cancer, a glioblastoma and an Ewing's sarcoma.
  • the lung cancer may be a small cell lung cancer.
  • the ovarian cancer may be a stromal ovarian cancer.
  • the thyroid cancer may be a medullary thyroid cancer.
  • the skin cancer may be a melanoma.
  • the skin cancer may be a neo-angiogenic skin cancer.
  • the pancreatic cancer may be an exocrine pancreatic cancer.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-Her2 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be a breast cancer.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-EGFRvIII antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be a glioma or a glioblastoma.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-CS1 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be a multiple myeloma.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-CLL-1 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be an acute myeloid leukemia.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-CD33 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be an acute myeloid leukemia.
  • the condition or disease may be a cancer.
  • the cancer may be a B-cell chronic lymphocytic leukemia.
  • the cancer may be a mantle cell lymphoma.
  • the cancer may be an acute lymphoblastic leukemia.
  • the condition or disease may be a cancer.
  • the cancer may be a B-cell chronic lymphocytic leukemia.
  • the cancer may be a mantle cell lymphoma.
  • the cancer may be an acute myeloid leukemia.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to an anti-IL13R ⁇ 2 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be a glioblastoma.
  • a disease or condition comprising administering a bispecific antibody comprising an anti-CD3 antibody or fragment thereof conjugated to a bscWue1 antibody or fragment thereof to a subject in need thereof.
  • the condition or disease may be a cancer.
  • the cancer may be a multiple myeloma.
  • the bispecific antibodies and compositions disclosed herein may be used to treat one or more diseases or conditions in a subject in need thereof.
  • the one or more diseases or conditions may be a cancer, a pathogenic infection, autoimmune disease, inflammatory disease, or genetic disorder.
  • the one or more diseases comprise a cancer.
  • the cancer may be a recurrent and/or refractory cancer. Examples of cancers include, but are not limited to, sarcomas, carcinomas, gliomas, lymphomas or leukemias.
  • the cancer may be a breast cancer.
  • the cancer may be a prostate cancer.
  • the cancer may be a lung cancer.
  • the cancer may be a glioma.
  • the cancer may be a glioblastoma.
  • the cancer may be a myeloma.
  • the cancer may be multiple myeloma.
  • the multiple myeloma may be a relapsed multiple myeloma.
  • the multiple myeloma may be refractory.
  • the leukemia may be acute myeloid leukemia.
  • the leukemia may be B-cell chronic lymphocytic leukemia.
  • the leukemia may be mantle cell leukemia.
  • Sarcomas are cancers of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.
  • Sarcomas include, but are not limited to, bone cancer, fibrosarcoma, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant schwannoma, bilateral vestibular schwannoma, osteosarcoma, soft tissue sarcomas (e.g.
  • alveolar soft part sarcoma alveolar soft part sarcoma, angiosarcoma, cystosarcoma phylloides, dermatofibrosarcoma, desmoid tumor, epithelioid sarcoma, extraskeletal osteosarcoma, fibrosarcoma, hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, and synovial sarcoma).
  • Carcinomas are cancers that begin in the epithelial cells, which are cells that cover the surface of the body, produce hormones, and make up glands.
  • carcinomas include breast cancer, pancreatic cancer, lung cancer, colon cancer, colorectal cancer, rectal cancer, kidney cancer, bladder cancer, stomach cancer, prostate cancer, liver cancer, ovarian cancer, brain cancer, vaginal cancer, vulvar cancer, uterine cancer, oral cancer, penile cancer, testicular cancer, esophageal cancer, skin cancer, cancer of the fallopian tubes, head and neck cancer, gastrointestinal stromal cancer, adenocarcinoma, cutaneous or intraocular melanoma, cancer of the anal region, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, cancer of the urethra, cancer of the renal pelvis, cancer of the ureter, cancer of the endometrium, cancer of the cervi
  • the cancer is a lung cancer.
  • Lung cancer may start in the airways that branch off the trachea to supply the lungs (bronchi) or the small air sacs of the lung (the alveoli).
  • Lung cancers include non-small cell lung carcinoma (NSCLC), small cell lung carcinoma, and mesotheliomia.
  • NSCLC non-small cell lung carcinoma
  • Examples of NSCLC include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
  • the mesothelioma may be a cancerous tumor of the lining of the lung and chest cavitity (pleura) or lining of the abdomen (peritoneum).
  • the mesothelioma may be due to asbestos exposure.
  • the cancer may be a brain cancer, such as a glioblastoma.
  • the cancer is a breast cancer.
  • the breast cancer is estrogen receptor positive, progesterone receptor positive and Her2 positive (triple positive).
  • the breast cancer is estrogen receptor negative, progesterone receptor negative and Her2 negative (triple negative).
  • the breast cancer is estrogen receptor positive and Her2 positive.
  • the breast cancer is estrogen receptor positive and Her 2 negative.
  • the breast cancer is estrogen receptor negative and Her2 positive.
  • the breast cancer is metastatic.
  • the cancer may be a central nervous system (CNS) tumor.
  • CNS tumors may be classified as gliomas or nongliomas.
  • the glioma may be malignant glioma, high grade glioma, diffuse intrinsic pontine glioma. Examples of gliomas include astrocytomas, oligodendrogliomas (or mixtures of oligodendroglioma and astocytoma elements), and ependymomas.
  • Astrocytomas include, but are not limited to, low-grade astrocytomas, anaplastic astrocytomas, glioblastoma multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.
  • Oligodendrogliomas include low-grade oligodendrogliomas (or oligoastrocytomas) and anaplastic oligodendriogliomas.
  • Nongliomas include meningiomas, pituitary adenomas, primary CNS lymphomas, and medulloblastomas. In some instances, the cancer is a meningioma.
  • the leukemia may be an acute lymphocytic leukemia, acute lymphoblastic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, or chronic myelocytic leukemia. Additional types of leukemias include hairy cell leukemia, chronic myelomonocytic leukemia, B-cell chronic lymphocytic leukemia and juvenile myelomonocytic leukemia.
  • Lymphomas are cancers of the lymphocytes and may develop from either B or T lymphocytes.
  • the two major types of lymphoma are Hodgkin's lymphoma, previously known as Hodgkin's disease, and non-Hodgkin's lymphoma.
  • Hodgkin's lymphoma is marked by the presence of the Reed-Sternberg cell.
  • Non-Hodgkin's lymphomas are all lymphomas which are not Hodgkin's lymphoma.
  • Non-Hodgkin lymphomas may be indolent lymphomas and aggressive lymphomas.
  • Non-Hodgkin's lymphomas include, but are not limited to, diffuse large B cell lymphoma, follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt's lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), extranodal marginal zone B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis.
  • MALT mucosa-associated lymphatic tissue lymphoma
  • MALT mucosa-associated lymphatic tissue lymphoma
  • small cell lymphocytic lymphoma mantle cell lymphoma
  • Burkitt's lymphoma mediastinal large B cell
  • the one or more diseases or conditions may be a pathogenic infection.
  • Pathogenic infections may be caused by one or more pathogens.
  • the pathogen is a bacterium, fungi, virus, or protozoan.
  • Exemplary pathogens include but are not limited to: Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio , or Yersinia .
  • the disease or condition caused by the pathogen is tuberculosis and the heterogeneous sample comprises foreign molecules derived from the bacterium Mycobacterium tuberculosis and molecules derived from the subject.
  • the disease or condition is caused by a bacterium is tuberculosis, pneumonia, which may be caused by bacteria such as Streptococcus and Pseudomonas , a foodborne illness, which may be caused by bacteria such as Shigella, Campylobacter and Salmonella , and an infection such as tetanus, typhoid fever, diphtheria, syphilis and leprosy.
  • the disease or condition may be bacterial vaginosis, a disease of the vagina caused by an imbalance of naturally occurring bacterial flora.
  • the disease or condition is a bacterial meningitis, a bacterial inflammation of the meninges (e.g., the protective membranes covering the brain and spinal cord).
  • Other diseases or conditions caused by bacteria include, but are not limited to, bacterial pneumonia, a urinary tract infection, bacterial gastroenteritis, and bacterial skin infection.
  • bacterial skin infections include, but are not limited to, impetigo which may be caused by Staphylococcus aureus or Streptococcus pyogenes ; erysipelas which may be caused by a streptococcus bacterial infection of the deep epidermis with lymphatic spread; and cellulitis which may be caused by normal skin flora or by exogenous bacteria.
  • the pathogen may be a fungus, such as, Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis , and Stachybotrys .
  • diseases or conditions caused by a fungus include, but are not limited to, jock itch, yeast infection, ringworm, and athlete's foot.
  • the pathogen may be a virus.
  • viruses include, but are not limited to, adenovirus, coxsackievirus, Epstein-Barr virus, Hepatitis virus (e.g., Hepatitis A, B, and C), herpes simplex virus (type 1 and 2), cytomegalovirus, herpes virus, HIV, influenza virus, measles virus, mumps virus, papillomavirus, parainfluenza virus, poliovirus, respiratory syncytial virus, rubella virus, and varicella-zoster virus.
  • diseases or conditions caused by viruses include, but are not limited to, cold, flu, hepatitis, AIDS, chicken pox, rubella, mumps, measles, warts, and poliomyelitis.
  • the pathogen may be a protozoan, such as Acanthamoeba (e.g., A. astronyxis, A. castellanii, A. culbertsoni, A. hatchetti, A. polyphaga, A. rhysodes, A. healyi, A. divionensis ), Brachiola (e.g., B. connori, B. vesicularum ), Cryptosporidium (e.g., C. parvum ), Cyclospora (e.g., C. cayetanensis ), Encephalitozoon (e.g., E. cuniculi, E. hellem, E.
  • Acanthamoeba e.g., A. astronyxis, A. castellanii, A. culbertsoni, A. hatchetti, A. polyphaga, A. rhysodes, A. healyi, A. divionensis
  • Brachiola e
  • Entamoeba e.g., E. histolytica
  • Enterocytozoon e.g., E. bieneusi
  • Giardia e.g., G. lamblia
  • Isospora e.g, I. belli
  • Microsporidium e.g., M. africanum, M. ceylonensis
  • Naegleria e.g., N. fowleri
  • Nosema e.g., N. algerae, N. ocularum
  • Pleistophora e.g., Trachipleistophora (e.g., T. anthropophthera, T. hominis )
  • Vittaforma e.g., V. corneae
  • the disease or condition may be an autoimmune disease or autoimmune related disease.
  • An autoimmune disorder may be a malfunction of the body's immune system that causes the body to attack its own tissues.
  • autoimmune diseases and autoimmune related diseases include, but are not limited to, Addison's disease, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome (APS), autoimmune aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune myocarditis, Behcet's disease, celiac sprue, Crohn's disease, dermatomyositis, eosinophilic fasciitis, erythema nodosum, giant cell arteritis (temporal arteritis), Goodpasture's syndrome, Graves' disease, Hashimoto's disease, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, juvenile arthritis, diabetes, juvenile diabetes, Kawasaki syndrome, Lambert-E
  • the disease or condition may be an inflammatory disease.
  • inflammatory diseases include, but are not limited to, alveolitis, amyloidosis, angiitis, ankylosing spondylitis, avascular necrosis, Basedow's disease, Bell's palsy, bursitis, carpal tunnel syndrome, celiac disease, cholangitis, chondromalacia patella, chronic active hepatitis, chronic fatigue syndrome, Cogan's syndrome, congenital hip dysplasia, costochondritis, Crohn's Disease, cystic fibrosis, De Quervain's tendinitis, diabetes associated arthritis, diffuse idiopathic skeletal hyperostosis, discoid lupus, Ehlers-Danlos syndrome, familial mediterranean fever, fascitis, fibrositis/fibromyalgia, frozen shoulder, ganglion cysts, giant cell arteritis, gout, Graves' Disease, HIV-
  • the antibodies disclosed herein may be used to modulate an immune response. Modulation of an immune response may comprise stimulating, activating, increasing, enhancing, or up-regulating an immune response. Modulation of an immune response may comprise suppressing, inhibiting, preventing, reducing, or downregulating an immune response.
  • the antibodies may comprise an anti-CD3 antibody or antibody fragment that may bind to a first cell and a second antibody or antibody fragment that may bind to a second cell. Binding of the antibody to the first and second cell may result in modulation of an immune response.
  • the first cell may be an immune cell.
  • the immune cell may be a hematopoietic cell.
  • the second cell may be an immune cell, healthy cell, cancer cell, bacteria, or virally-infected.
  • UCHT1-Fab sequences were obtained from the literature and inserted into a pBAD vector behind the stII signal sequence.
  • the sites for unnatural amino acid incorporation (light chain threonine 109 (LC-Thr109), light chain serine 202 (LC-Ser202), heavy chain alanine 123 (HC-A123), and heavy chain lysine 138 (HC-Lys138)) were quickchanged (QuikChange® Stratagene) to TAG amber nonsense codon.
  • two residues LC-Ser202 and HC-Lys138 were mutated to TAG amber nonsense codon.
  • FIG. 1 depicts a ribbon diagram of the UCHT1-Fab fragment.
  • the pBAD vector was co-transformed with pULTRA-pAcF (a vector containing orthogonal M. jannaschii tRNA and aminoacyl-tRNA synthetase specific for pAcF) in DH10B cells.
  • the cells were grown in LB media (2 L) supplemented with 100 mg/ml ampicillin, 25 mg/ml chloramphenicol, and 1 mM pAcF at 37° C. and 250 rpm. At OD 600 0.8, cells were induced with 0.2% arabinose and moved to 30° C. for 20 hours at 270 rpm.
  • Cells were harvested and proteins were extracted by incubating with 150 mL of periplasmic lysis buffer (20% sucrose, 30 mM Tris, pH 8, 1 mM EDTA, and 0.2 mg/mL lysozyme) for 30 min at 37° C. Extracts were clarified by centrifugation (18000 rpm, 30 min), filtered through 0.22 micron filter, and loaded onto Protein G column (GE healthcare). The column was washed with 20 bed volumes of 50 mM NaOAc, pH 5.2, and proteins were eluted with 10 bed volumes of 100 mM glycine, pH 2.8. The eluents were immediately neutralized by adding 10% of 1 M Tris, pH 8, and dialysed against PBS for long-term storage.
  • periplasmic lysis buffer (20% sucrose, 30 mM Tris, pH 8, 1 mM EDTA, and 0.2 mg/mL lysozyme
  • Our strategy takes advantage of genetically encoded unnatural amino acids with orthogonal chemical reactivity relative to the canonical twenty amino acids to site-specifically modify antibody fragments.
  • an evolved tRNA/aminoacyl-tRNA synthetase pair to site-specifically incorporate p-acetylphenylalanine (pAcF, FIG. 2A ) at defined sites in each of two Fab fragments in response to an amber nonsense codon.
  • the mutant Fab fragments were then selectively coupled by stable oxime formation using the alkoxy-amine termini of two bifunctional linkers ( FIG. 2B ).
  • the two Fab-linker conjugates were linked to each other in order to obtain the heterodimer through a copper-free [3+2] Huisgen-cycloaddition (“Click” reaction) ( FIG. 2C ).
  • This approach has a number of advantages over recombinant technologies and conventional coupling chemistries. For example, the use of bioorthogonal chemistries produces homogeneous, chemically-defined products; variable linker lengths and conjugation sites on the antibody may be easily optimized to ensure flexibility and good efficacy for each specific application; sequences from existing monoclonal antibodies may be directly adopted; and the modular approach easily and rapidly allows for combinatorial generation of diverse heterodimers (antibodies, enzymes, cytokines, etc.)
  • FIG. 3A-E depict ESI-MS analysis of Fab fragments before linker and after linker conjugation.
  • FIG. 3B depicts Herceptin Fab-(PEG) 4 -Az;
  • FIG. 9C depicts Herceptin Fab-(PEG) 4 -Octyne;
  • FIG. 3B depicts Herceptin Fab-(PEG) 4 -Az;
  • FIG. 9C depicts Herceptin Fab-(PEG) 4 -Octyne;
  • FIG. 3F-J depict deconvoluted mass spectrum of Fab fragments before and after linker conjugation.
  • FIG. 3G depicts Herceptin Fab-(PEG) 4 -Az;
  • FIG. 3H depicts Herceptin Fab-(PEG) 4 -Octyne;
  • FIG. 3J depicts UCHT1 Fab-(PEG) 4 -Octyne.
  • pAcPhe was substituted at HC-K138 in the anti-anti-CD3 antibody, UCHT1.
  • This site is distal to the antigen binding site and, when conjugated to the LC-5202 mutant anti-HER2 Fab with the same polyethylene glycol linker used above, should be long and flexible enough to allow the resulting bispecific antibody to productively bind both a CD3 positive T-cell and the HER2 positive target cell simultaneously.
  • UCHT1 Fab was expressed in E. coli by the same method as described for anti-HER2 Fab and in Example 2, and the cyclooctyne linker-modified anti-CD3 was prepared as described in Example 7 in >95% yield as confirmed by ESI-MS ( FIG. 3E , 3 J).
  • FIG. 4A shows the SDS-PAGE of the anti-HER2/anti-CD3 heterodimer.
  • FIG. 4B shows the size exclusion chromatography FPLC trace of the anti-HER2/anti-CD3 heterodimer.
  • FIG. 5A shows the FACS analysis of CD3-positive (Jurkat) cells treated with anti-k-PE (line 1), anti-CD3 Fab (line 2), anti-Her2 Fab (line 3) or anti-Her2/anti-CD3 heterodimer (line 4).
  • FIG. 5A shows the FACS analysis of CD3-positive (Jurkat) cells treated with anti-k-PE (line 1), anti-CD3 Fab (line 2), anti-Her2 Fab (line 3) or anti-Her2/anti-CD3 heterodimer (line 4).
  • 5B shows the FACS analysis of HER2-positive (SK-BR-3) cells treated with anti-k-PE (line 1), anti-CD3 Fab (line 2), anti-Her2 Fab (line 3) or anti-Her2/anti-CD3 heterodimer (line 4).
  • SK-BR-3 cells and Jurkat cells were first stained with Mito Tracker Red (Invitrogen) and carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), respectively.
  • the labeled Jurkat cells were incubated with 100 nM of the anti-HER2/anti-CD3 heterodimer in RPMI media supplemented with 10% FBS (fetal bovine serum) at 4° C. for 30 minutes, and excess conjugate was washed away before mixing the Jurkat cells with SK-BR3 cells.
  • FBS fetal bovine serum
  • a 1:1 mixture of unconjugated anti-CD3 and anti-HER2 Fabs was used as a negative control under the same labeling conditions.
  • the cells were incubated at 37° C. for 6 hours, allowing the adherent SK-BR-3 cells to attach to the plate; excess Jurkat cells were removed by gentle washing with media.
  • significantly more Jurkat cells small light grey circles, highlighed by horizontal arrows
  • were bound to the SK-BR-3 cells larger dark grey circles, highlighed by vertical arrows in FIG. 5C , no arrows in FIG. 5D ) after washing compared to cells incubated with the mixture of unconjugated Fabs ( FIG.
  • FIG. 5C-D shows the overlay of SK-BR-3 cells and Jurkat cells treated with the anti-HER2/anti-CD3 Fab heterodimer.
  • FIG. 5D shows the overlay of SK-BR-3 cells and Jurkat cells treated with a 1:1 mixture of unconjugated anti-CD3 and anti-HER2 Fabs.
  • PBMCs peripheral blood mononuclear cells
  • Ficoll GE Healthcare
  • target cells HER2-transfected MDA-MB-435 (33)
  • Non-transfected MDA-MB-435 cells were used as an isogenic negative control.
  • a 1:1 mixture of unconjugated anti-HER2 and anti-CD3 Fabs were used as an additional negative control to further demonstrate that cytotoxicity was due to bispecific antibody-based interactions.
  • FIG. 6 shows the dose-dependent cytotoxicity with MDA-MB-435/HER2+ cells in the presence of human PBMCs and antibody heterodimer. Different concentrations of anti-HER2/anti-CD3 Fab heterodimer (circles, line 1), or a 1:1 mixture of unconjugated anti-HER2 Fab and anti-CD3 Fab (square, line 2) were incubated with MDA-MB-435/HER2+ cells.
  • cytotoxicity was measured by levels of LDH (lactate dehydrogenase) release from lysed cells using the Cytotox 96 Nonradioactive Cytotoxicity Assay Kit (Promega).
  • LDH lactate dehydrogenase
  • MDA-MB-435/HER2+ or MDA-MB-435/HER2 ⁇ cells with no PBMCs were incubated and lysed using the lysis buffer (provided in the assay kit) as maximum cytotoxicity controls. The absorbance at 490 nm was recorded using SpectraMax 250 plate reader (Molecular Devices Corp.). Percent cytotoxicity was calculated by:
  • lysis of HER2 positive target cells was observed in a dose dependent manner only when the conjugated anti-HER2/anti-CD3 heterodimer was present ( FIG. 6 , cicles, line 1); the half maximal effective concentration (EC 50 ) was ⁇ 20 pM.
  • HER2-negative MDA-MB-435 cells were not affected by the heterodimer, and neither cell line was affected by the unconjugated Fab mixture.
  • the percent cytoxicity of the HER2 positive and HER2 negative cells is shown in Table 1.
  • FIG. 7A shows the microscopic images from the cytoxicity assay in HER2 ⁇ cells treated with the 1:1 mixture of unconjugated anti-HER2 Fab and anti-CD3 Fab.
  • FIG. 7B shows the microscopic images from the cytoxicity assay in HER2 ⁇ cells treated with the anti-HER2/anti-CD3 Fab heterodimer.
  • FIG. 7C shows the microscopic images from the cytoxicity assay in HER2+ cells treated with the 1:1 mixture of unconjugated anti-HER2 Fab and anti-CD3 Fab.
  • FIG. 7D shows the microscopic images from the cytoxicity assay in HER2+ cells treated with the anti-HER2/anti-CD3 Fab heterodimer.
  • NOD-SCID NOD.CB17-Prkdc scid /NCrCrl mice.
  • Others have also reported better efficiency with NOD-SCID IL2-gamma-knockout mice (34) or by supplementing with irradiation (35).
  • the simplest model includes premixing and co-injecting the tumor cells and purified human PBMCs (36, 37). While, this works for a preventative treatment model, it is not ideal for treatment models.
  • Tumor cells like MDA-MB-435 Her2-transfected, often take 1-2 weeks to reach the 100 mm 3 tumor size that is often required for treatment models before administrating drug.
  • a complication is that hPBMCs have been reported to only remain in NOD-SCID mice for 2 weeks, potentially reducing the efficacy by the time drug administration begins (37).
  • Others have explored intraperitoneal (IP) and intravenous (IV) injection of PBMCs to reconstitute a human immune system in the mouse (38, 39). This method is more difficult and often is only retroactively confirmed of correct reconstitution by performing histology on the spleen.
  • IP intraperitoneal
  • IV intravenous
  • mice were divided into three groups: 1:1 ratio (2 ⁇ 10 6 MDA-MB-435/Her2 + cells, 2 ⁇ 10 6 hPBMCs); 1:2 ratio (2 ⁇ 10 6 MDA-MB-435/Her2 + cells, 4 ⁇ 10 6 hPBMCs); and 1:5 (2 ⁇ 10 6 MDA-MB-435/Her2 + cells, 1 ⁇ 10 7 hPBMCs). All groups were inject with 1:1 ratio of premixed cells to MatriGel above the right shoulder by subcutaneous injection (SC). Tumor size were monitored by caliper measurements of length and width every 3-4 days and approximated by the formula:
  • Tumor volume (mm 3 ) (Length ⁇ width ⁇ width)/2
  • FIG. 8 shows growth curves of MDA-MB-435/Her2′ premixed with hPBMC and Matrigel.
  • the ratios of cancer cells to hPBMCs were 1:1 (square), 1:2 (triangle), and 1:5 (x) with 3 NOD-SCID mice per group.
  • Tumors in 1:1 group grew very fast, tumors in 1:2 group began to grow after 2 weeks, and tumors in 1:5 group did not grow at all. As predicted, having too many hPBMCs inhibits tumor growth.
  • FIG. 9 shows the results for the preventative in vivo xenograft model with premixed MDA-MB-435/Her2′ cancer cells (2 ⁇ 10 6 cells), hPBMCs (4 ⁇ 10 6 cells), and MatriGel.
  • FIG. 10 shows the IVIS imaging of two heterodimer treatment mice (left two) and two unconjugated Fabs mice (right two). Luciferin was inject into each mice and incubated for 10 minutes before capturing the image.
  • the MDA-MB-435/Her2′ were transfected to include the firefly luciferase gene.
  • the MatriGel may have formed a matrix where it protected a small amount of tumor cells from being killed or small population of Her2 ⁇ or Her2 low cells in the cancer cell line had escaped death.
  • the excised tumor at the end of Day 20 did confirm that the majority of the remaining bump in the treatment group was due to MatriGel, which is often soft and white while tumor is solid and red (due to blood vessels) ( FIG. 11 ).
  • FIG. 11 shows the excised tumor or MatriGel from the preventative anti-Her2/anti-CD3 Fab heterodimer study.
  • the “tumors” left from the heterodimer treatment group is most likely residual MatriGel, which is characterized by being soft and white.
  • FIG. 12 shows a general scheme for synthesizing bifunctional linkers.
  • Triphenylphosphine 430 mg, 1.64 mmol
  • N-hydroxyphthalimide 270 mg, 1.66 mmol
  • DIAD 0.32 mL, 1.6 mmol
  • 1-azido-3,6,9-trioxaundecane-1-ol 300 mg, 1.37 mmol
  • CH 2 Cl 2 20 mL
  • the solvent was removed under reduced pressure, and the residue was purified by flash column chromatography on silica gel (Hex-EtOAc, 1:1) to afford compound 5 (426 mg, 85%).
  • TEA (1R,8S,9R)-bicyclo[6.1.0]non-4-yn-9-ylmethyl(4-nitrophenyl)carbonate (compound 6, 270 mg, 0.86 mmol) in DMF (10 mL).
  • Herceptin-Fab and UCHT1-Fab sequences were obtained from the literature and inserted into a pBAD vector behind the stII signal sequence.
  • the sites for unnatural amino acid incorporation (LC-Ser202 for Her2 Fab, HC-Lys138 for UCHT1) were quickchanged (Stratagene) to TAG amber nonsense codon.
  • the pBAD vector was co-transformed with pEVOL-pAcF (a vector containing orthogonal M. jannaschii tRNA and aminoacyl-tRNA synthetase specific for pAcF in DH10B cells.
  • the cells were grown in LB media (2 L) supplemented with 100 mg/ml ampicillin, 25 mg/ml chloramphenicol, and 1 mM pAcF at 37° C. and 250 rpm. At OD 600 0.8, cells were induced with 0.2% arabinose and moved to 30° C. for 16 hours at 270 rpm. Cells were harvested and proteins were extracted by incubating with 150 mL of periplasmic lysis buffer (20% sucrose, 30 mM Tris, pH 8, 1 mM EDTA, and 0.2 mg/mL lysosyme) for 30 min at 37° C.
  • periplasmic lysis buffer (20% sucrose, 30 mM Tris, pH 8, 1 mM EDTA, and 0.2 mg/mL lysosyme
  • Extracts were clarified by centrifugation (18000 rpm, 30 min), filtered through 0.22 micron filter, and loaded onto Protein G column (GE healthcare).
  • the column was washed with 20 bed volumes of 50 mM NaOAc, pH 5.2, and proteins were eluted with 10 bed volumes of 100 mM glycine, pH 2.8.
  • the eluents were immediately neutralized by adding 10% of 1 M Tris, pH 8, and dialysed against PBS for long-term storage.
  • the antibodies (anti-HER2 Fab, anti-CD3 Fab) were buffer exchanged into 100 mM NaOAc, pH 4.5, and the concentrations were adjusted to ⁇ 5 mg/mL.
  • the oxime ligation was conducted with 50 times molar excess of linkers, and the reaction was complete within 24 hours, as monitored by LC-MS. Excess linkers were removed by size filtration (Amicon 10K) or size exclusion column (Superdex 75) chromatography, the antibodies were buffer exchanged into PBS, pH 7.4, and the protein concentrations were adjusted to 10 mg/mL.
  • Fab-Az conjugate and Fab-cyclooctyne conjugate were mixed at 1:1 molar ratio ( ⁇ 10 mg in total), and incubated for 2 days at 37° C.
  • Dimeric Fab conjugate was purified from unreacted Fabs by size exclusion column (Superdex 200) ( FIG. 4B ).
  • SK-BR-3 cells were trypsinized (0.05% trypsin/EDTA, Hyclone) and washed with PBS.
  • Jurkat cells in suspension were directly used without trypsinization.
  • Cells (0.2 ⁇ 10 6 ) were blocked with 3% BSA in PBS (200 ml) for 1 hour at 4° C. then incubated with 100 nM of primary antibodies for 1 hour at 4° C.
  • Cells were washed (cold PBS 1 ml) twice, resuspended in 200 ml of cold PBS, and incubated with secondary goat anti-human kappa PE conjugated antibody (100X, Southern Biotech) for 30 min at 4° C.
  • SK-BR-3 and Jurkat cells were stained with Mito Trakcer Red (Invitrogen) and CFSE (carboxyfluorescein succinimidyl ester, Invitrogen), respectively, following the manufacturer's protocol.
  • Jurkat cells (2 ⁇ 10 4 ) were incubated with anti-HER2/anti-CD3 heterodimer (100 nM) in 200 mL of PBS for 30 min at 4° C. In a separate tube, Jurkat cells were incubated with a 1:1 mixture of anti-HER2 Fab and anti-CD3 Fab (100 nM each) as negative controls.
  • the Jurkat cells were resuspended with 200 ml of RPMI media with 10% FBS, then mixed with SK-BR-3 cells (2 ⁇ 10 3 ) in the same media (200 mL). Two hundred microliters of the cell mixture was added into a clear bottom 96 well plate, and incubated at 37° C. and 5% CO 2 . After 6 hours, wells were gently washed with PBS (200 mL) 4 times and imaged on a fluorescent microscope (Eclipse Ti, Nikon) under FITC (for CFSE) and rhodamine (for Mitro Traker Red) filters. The images from each filter were combined to produce an overlay image as seen in FIG. 7C .
  • PBMCs Peripheral blood mononuclear cells
  • PBMCs Peripheral blood mononuclear cells
  • HER2-transfected MDA-MB-435 or non-transfected MDA-MB-435 cells were dissociated with 0.05% tryspin/EDTA solution (HyClone) and washed with RPMI with 10% FBS. 1 ⁇ 10 4 target cells were mixed with PBMCs at 1:10 ratio in 100 ⁇ l, and incubated with different concentrations of conjugated and unconjugated anti-Her2/anti-CD3 Fabs (10 ⁇ L in PBS) for 17 hours at 37° C. Cytotoxicity of each well was measured for LDH (lactate dehydrogenase) levels in supernatant using Cytotox-96 non-radioactive cytotoxicity assay kit (Promega).
  • LDH lactate dehydrogenase
  • Lysis solution (10 ⁇ L, provided in the same kit) was added to wells with only target cells to get the maximum killing, and spontaneous killing was measured from wells with effector and target cells treated with vehicle (10 ⁇ L PBS). The absorbance at 490 nm was recorded using SpectraMax 250 plate reader (Molecular Devices Corp.). Percent cytotoxicity was calculated by:
  • the first step of bispecific antibody construction using our method was conjugating the bifunctional linker to the respective antibody components.
  • Linker bearing the azide was conjugated to anti-Her2 IgG and Fab, while the linker bearing cycloocyne was conjugated to anti-CD3 Fab single (HC-K138X) and double mutant (LC-5202X, HC-K138X).
  • the oxime ligation was conducted with 50-fold molar excess of linker in acetate buffer pH 4.5 at 37° C. for 16-48 hours. Complete conjugation was monitored by LCMS of the anti-CD3 Fab conjugation reaction (IgG reaction would have required additional preparation for LCMS).
  • the Podracer compound utilized anti-Her2-Fab-Az and anti-CD3-Fab-Oct (single mutant) at 1:8 molar ratio at a final concentration of 10 mg/mL. All constructs were incubated at 37° C. and monitored every other day by SDS-PAGE for reaction completion, which usually took about 7-10 days. All conjugates were purified by Superdex 200 size exclusion column at 0.2 mL/min with PBS+100 mM NaCl as the mobile phase. SDS-PAGE was used to analyze each 0.5 mL fraction and the most pure fractions were combined and used for subsequent testing. Purified conjugates were then further analyzed by non-reducing and reducing SDS-PAGE gels.
  • Her2 expression level on different cell lines were determined by Western blot. 1 ⁇ 10 4 Her2 positive cells (SK-BR-3, HCC-1954, MDA-MB-435/Her2 + ) and 1 ⁇ 10 6 Her2 “negative” cells (MDA-MB-231, MDA-MB-435/Her2 ⁇ , CHO) were washed once with PBS and resuspended in 30 ⁇ L of Cell Lytic M buffer (Sigma) and incubated at 4° C. for 30 min. The solution was centrifuged and the supernatant was mixed with SDS loading buffer for SDS-PAGE.
  • the general method for expressing proteins such as Z-domain, T4 lysozyme (T4L) and LamB transmembrane protein were similar to that which was previously described (2).
  • the gene of interest (with TAG in the codon position that is desired to be modified with the UAA) is usually on one plasmid and the desired tRNA and amino-acyl tRNA synthetase pair are on a different plasmid with a different selection marker and origin of replication.
  • the most optimized system to date is the pEVOL plasmid, which has one optimized tyrosyl-tRNA that responds to the amber codon and two copies of RS: one behind a constitutive promoter to provide a basal level of expression and one behind the arabinose promoter for strong inducible expression.
  • the pEVOL plasmid chloramphenicol resistance
  • pET vector ampicilin resistance
  • the co-transformed cells were grown in 2 ⁇ YT or LB (required for LamB expression) at 37° C. overnight or until saturation.
  • the cultures were then inoculated at OD 600 of 0.2 into fresh media containing 1 mM UAA at 37° C. At OD 600 of 0.8-1.0, 1 mM IPTG and 0.02% arabinose were added and the cultures were moved to 30° C. for overnight growth. The next day, cells were harvested for downstream application. Z-domain and T4L that contain C-terminal His6 tags were sonicated, clarified of precipitates, and incubated with Ni-NTA resin at room temperature for 30 min. Resin was washed twice in desktop centrifuge columns and eluted with buffer containing immidozole. For conjugation, protein was often buffer exchanged into PBS using Amicon centrifugal columns.
  • Anti-CD20 for B cell lymphoma
  • anti-CD3 Fab fragments and heterodimers were constructed according to methods as described in the previous examples. Briefly, we incorporated pAcF into anti-CD20 Fabs (S202pAcF), modified them with bifunctional linkers, and conjugated to anti-CD3 Fab to prepare anti-CD20/anti-CD3 bispecific antibody. All of the conjugation and purification steps followed the procedure described for the preparation of the anti-Her2/anti-CD3 bispecific antibody.
  • FIG. 13 depicts a graph of the cytoxicity of Ramos cells treated with an anti-CD20/anti-CD3 bispecific antibody (circle) or treated with unconjugated Fab fragments (square).
  • Table 3 shows the cytoxicity of Ramos cells treated with an anti-CD20/anti-CD3 bispecific antibody or treated with unconjugated Fab fragments.
  • Anti-EGFR for KRAS/BRFA mutated colorectal or lung cancer
  • anti-CD3 Fab fragments and heterodimers were constructed according to methods as described in the previous examples. Briefly, we incorporated pAcF into anti-EGFR Fabs (S202pAcF), modified them with bifunctional linkers, and conjugated to anti-CD3 Fab to prepare anti-EGFR/anti-CD3 bispecific antibody. All of the conjugation and purification steps followed the procedure described for the preparation of the anti-Her2/anti-CD3 bispecific antibody.
  • FIG. 14 and Table 4 shows the cytoxicity of A549 cells treated with an anti-EGFR/anti-CD3 bispecific antibody (circle) or treated with unconjugated Fab fragments (square).
  • FIG. 15 and Table 5 shows the cytoxicity of HT29 cells treated with an anti-EGFR/anti-CD3 bispecific antibody (circle) or treated with unconjugated Fab fragments (square).
  • FIG. 16 and Table 6 shows the cytoxicity of AGS cells treated with an anti-EGFR/anti-CD3 bispecific antibody (circle) or treated with unconjugated Fab fragments (square).
  • BiFab antibodies were created by expression of the UCHT1 Fab harboring a p-acetylphenylalanine (pAcF) residue in place of lysine at residue 138 (K138X).
  • the protein was expressed in E. coli , purified by affinity column and conjugated to the Tet-TEG-ONH2 heterobifunctional linker via oxime ligation using previously reported conditions (buffer pH 4.5, 30-fold excess, overnight).
  • the CS1 antibody was expressed in similar fashion using previously reported conditions.
  • the CS1 Fab was independently conjugated to TCO-TEG-ONH2 (subsequent generations were produced using a TCO linker ( FIG. 2 )). Conjugated CS1 was ligated to UCHT1-Tet Fab using previously reported “click” chemistry. Antibodies were purified over size-exclusion chromatography before testing in cytotoxicity assays.
  • Cells were harvested at 5 k rpm for 30 min and cell pellets were frozen at ⁇ 80° C. followed by thawing at room temperature. Cell pellets were resuspended in periplasmic lysis buffer (30 mM Tris-HCl, 1 mM EDTA, 20% sucrose pH 7.5 and 0.2 mg/mL lysozyme) and the cell suspension incubated at 37° C. with shaking for 20-30 min. Lysates were cleared at 14,000 rpm for 45 min and filtered through a 0.2 ⁇ M filter to remove particulates.
  • periplasmic lysis buffer (30 mM Tris-HCl, 1 mM EDTA, 20% sucrose pH 7.5 and 0.2 mg/mL lysozyme
  • the cleared and filtered lysates were applied to pre-equilibrated columns packed with Protein G Sepharose resin (GE Healthcare), washed with 50 mM sodium acetate (pH 5.0), and protein eluted with 100 mM glycine (pH 2.8).
  • Protein G Sepharose resin GE Healthcare
  • Fabs were buffer-exchanged into 100 mM sodium acetate (pH 4.5) 3 times using Amicon concentrators (10,000 MWCO).
  • Fab ⁇ 5 mg/mL was conjugated to the appropriate heterobifunctional linker (TCO-TEG-ONH2 for UCHT1, and Tet-TEG-ONH2 for CS1) ( FIG. 17B ) at 50-fold excess linker to Fab, overnight at 37° C. (oxime ligation).
  • the reactions were buffer exchanged into PBS pH 7.5 and purified by size-exclusion chromatography (Superdex 200), and the products confirmed by mass spectrometry.
  • Coupling of CS1 Fab to UCHT1 Fab was carried out by mixing the two Fab-linkers in a 1:1 molar ratio and incubating at 37° C. for ⁇ 16 h.
  • BiFab was purified using size-exclusion chromatography (Superdex 200), and the product confirmed by SDS-PAGE ( FIG. 17A ) and mass spectrometry analysis.
  • PBMCs Peripheral blood mononuclear cells
  • PBMCs Peripheral blood mononuclear cells
  • Equal volumes of target cells and effectors were mixed together to obtain an effector:target ratio of 10:1, and dispensed in 100 ⁇ L volumes in a 96-well round-bottom plate.
  • the effector-target mixtures were incubated with different concentrations of BiFabs and unconjugated Fabs single or mixed (ranging from 10 nM down to 50 fM) for 24 hours at 37° C. Cytotoxicity of each well was measured as levels of LDH (lactate dehydrogenase) in supernatant using Cytotox-96 non-radioactive cytotoxicity assay kit (Promega).
  • FIG. 17C shows an increasing cytotoxicity as a result of increasing the concentration of the ⁇ CS-1/ ⁇ CD3 BiFab.
  • a 10 ul of 0.1-1.0 mg/mL solution of Fab in PBS buffer was injected onto an LC Agilent 6520 Q-TOF mass spectrometer equipped with a 150 ⁇ 2.1 mm C8 column using a Water/Acetonitrile (0.1% formic acid) gradient (20%-80% over 10 min).
  • electrospray settings were as follows: gas temp 350 deg C, drying gas 10 l/min, nebulizer 40 psig, fragmentor 200, VCap 4500, and TOF settings were standard (3200) range, 2 GHz, extended dynamic range.
  • FIG. 19 A-C shows the deconvolution results for unconjugated CS1 and UCHT1, CS1 and UCHT1 conjugated to their respective linkers, and the CS1 ⁇ UCHT1 biFab, and Table 7 shows the summary of masses.
  • Anti-CLL1 and anti-CD3 Fab containing unnatural amino acid (pAcPhe) at heavy chain 138 position were expressed following the standard protocol.
  • the Fab fragments were modified with hetero-bifunctional linkers and conjugated with anti-CD3 Fab, also following standard protocol described in the synthesis of other bispecific antibodies.
  • HL60 CD33 and CLL-1 positive
  • CD3-positive Jurkat cells 0.2 ⁇ 10 6
  • PBS 200 ml
  • HL60 CD33 and CLL-1 positive
  • CD3-positive Jurkat cells 0.2 ⁇ 10 6
  • PBS 200 ml
  • 100 nM of primary antibodies 100 nM
  • Cells were washed (cold PBS 1 mL) twice, resuspended in 0.2 mL of cold PBS, and incubated with secondary goat anti-human kappa PE conjugated antibody (100X, Southern Biotech) for 30 min at 4° C.
  • Cells were washed twice with 1 mL of cold PBS before analysis on a BD LSR II flow cytometer (Beckton Dickinson Immunocytometry Systems) with 10,000 cell events per sample.
  • FIG. 20A anti-CLL-1/anti-CD3, FIG. 20B , anti-CD33/anti-CD3
  • the above procedure was repeated in round-bottomed 96-well format with different concentrations of primary antibodies.
  • Cells were injected using high-throughput sampler (BD HTS). Data was analyzed using FlowJo software (Tree Star Inc.).
  • PBMCs Purified PBMCs were washed and incubated in flasks in RPMI 1640 medium with 5% FBS for 1 hour at 37° C., before washing with medium and adjusting concentration to 2 ⁇ 10 ⁇ 6 cells/ml.
  • HL60 cells were stained using PKH26 Red Fluorescent Cell linker kit (Sigma Aldrich) and the volume adjusted to give a final concentration of 0.2 ⁇ 10 ⁇ 6 cells/ml.
  • Equal volumes of target cells and effectors were mixed together to obtain an effector:target ratio of 10:1, and dispensed in 100 ⁇ L volumes in a 96-well round-bottom plate.
  • the effector-target mixtures were incubated with different concentrations of BiFabs and unconjugated Fabs single or mixed for 24 hours at 37° C. After 24 hours, wells were treated with 7-aminoactinomycin D (7-AAD, BD Biosciences) for 30 min at room temperature to stain dead cells. For flow cytometry, unstained target cells, target cells stained with PKH26 only, and target cells stained with 7-AAD only (after treatment with ice-cold 90% methanol on ice for 30 min) were used as controls. Samples were read using LSRII Flow Cytometer (BD), and analyzed using FlowJo. Percentage viability was calculated as the ratio of live target cells in treated population to that in the untreated population (see FIG. 21A anti-CD33/anti-CD3 and FIG. 21B anti-CLL-1/anti-CD3).
  • 7-aminoactinomycin D 7-aminoactinomycin D
  • IFN- ⁇ and IL-2 in supernatant were measured by ELISA (DuoSet ELISA Kit, R&D systems) (see FIG. 22A for IFN- ⁇ and FIG. 22B for IL-2).
  • BiFab antibodies were created by expression of the UCHT1 Fab harboring at p-acetylphenylalanine (pAcF) residue in place of lysine at residue 138 (K138X).
  • the protein was expressed in E. coli , purified by affinity column and conjugated to the TCO-TEG-ONH2 heterobifunctional linker ( FIG. 17B ) via oxime ligation (buffer pH 4.5, 30-fold excess, overnight.
  • Hu806 antibody was expressed in similar fashion using previously reported conditions. These antibodies harbored the pAcF residue in place of the serine 202 residue (S202X).
  • Hu806 S202LC pAcF Fab was independently conjugated to Tet-TEG-ONH2 ( FIG. 17B )
  • Hu806-Tet Fab was then ligated to UCHT1-TCO Fab using “click” chemistry.
  • Antibodies were purified over size-exclusion chromatography before testing in cytotoxicity assays
  • Cells were harvested at 5 k rpm for 30 min and cell pellets were frozen at ⁇ 80° C. followed by thawing at room temperature. Cell pellets were resuspended in periplasmic lysis buffer (30 mM Tris-HCl, 1 mM EDTA, 20% sucrose pH 7.5 and 0.2 mg/mL lysozyme) and the cell suspension incubated at 37° C. with shaking for 20-30 min. Lysates were cleared at 14,000 rpm for 45 min and filtered through a 0.2 ⁇ M filter to remove particulates.
  • periplasmic lysis buffer (30 mM Tris-HCl, 1 mM EDTA, 20% sucrose pH 7.5 and 0.2 mg/mL lysozyme
  • the cleared and filtered lysates were applied to pre-equilibrated columns packed with Protein G Sepharose resin (GE Healthcare), washed with 50 mM sodium acetate (pH 5.0), and protein eluted with 100 mM glycine (pH 2.8).
  • Protein G Sepharose resin GE Healthcare
  • Fabs were buffer-exchanged into 100 mM sodium acetate (pH 4.5) 3 times using Amicon concentrators (10,000 MWCO).
  • Fab ⁇ 5 mg/mL was conjugated to the appropriate heterobifunctional linker (TCO-TEG-ONH2 for UCHT1, and Tet-TEG-ONH2 for hu806) at 50-fold excess linker to Fab, overnight at 37° C. (oxime ligation).
  • the reactions were buffer exchanged into PBS pH 7.5 and purified by size-exclusion chromatography (Superdex 200), and the products confirmed by mass spectrometry.
  • PBMCs Peripheral blood mononuclear cells
  • PBMCs Peripheral blood mononuclear cells
  • Target cells A431 (EGFR+) were washed with RPMI 1640 medium with 5% FBS and adjusted to a concentration of 0.2 ⁇ 10 ⁇ 6 cells/ml. Equal volumes of target cells and effectors were mixed together to obtain an effector:target ratio of 10:1, and dispensed in 100 ⁇ L volumes in a 96-well round-bottom plate. The effector-target mixtures were incubated with different concentrations of BiFabs and unconjugated Fabs single or mixed for 24 hours at 37° C. Cytotoxicity of each well was measured as levels of LDH (lactate dehydrogenase) in supernatant using Cytotox-96 non-radioactive cytotoxicity assay kit (Promega).
  • LDH lactate dehydrogenase
  • Lysis solution provided in the same kit, was added to wells with only target cells to get the maximum killing, and spontaneous killing was measured from wells with untreated effector and target cells.
  • the absorbance at 490 nm was recorded using EnVision Multilabel Reader (Perkin Elmer). Percent cytotoxicity was calculated using the following formula:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
US14/774,649 2013-03-14 2014-03-14 Bispecific antibodies and uses thereof Abandoned US20160017058A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/774,649 US20160017058A1 (en) 2013-03-14 2014-03-14 Bispecific antibodies and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361783426P 2013-03-14 2013-03-14
US201361839330P 2013-06-25 2013-06-25
PCT/US2014/028612 WO2014153002A1 (en) 2013-03-14 2014-03-14 Bispecific antibodies and uses thereof
US14/774,649 US20160017058A1 (en) 2013-03-14 2014-03-14 Bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
US20160017058A1 true US20160017058A1 (en) 2016-01-21

Family

ID=51581385

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/774,649 Abandoned US20160017058A1 (en) 2013-03-14 2014-03-14 Bispecific antibodies and uses thereof
US14/774,647 Active 2035-08-22 US10351626B2 (en) 2013-03-14 2014-03-14 Targeting agent antibody conjugates and uses thereof
US15/268,389 Abandoned US20170002076A1 (en) 2013-03-14 2016-09-16 Targeting agent antibody conjugates and uses thereof
US16/420,062 Active 2035-02-27 US11377496B2 (en) 2013-03-14 2019-05-22 Targeting agent antibody conjugates and uses thereof
US17/847,054 Abandoned US20220396621A1 (en) 2013-03-14 2022-06-22 Targeting agent antibody conjugates and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/774,647 Active 2035-08-22 US10351626B2 (en) 2013-03-14 2014-03-14 Targeting agent antibody conjugates and uses thereof
US15/268,389 Abandoned US20170002076A1 (en) 2013-03-14 2016-09-16 Targeting agent antibody conjugates and uses thereof
US16/420,062 Active 2035-02-27 US11377496B2 (en) 2013-03-14 2019-05-22 Targeting agent antibody conjugates and uses thereof
US17/847,054 Abandoned US20220396621A1 (en) 2013-03-14 2022-06-22 Targeting agent antibody conjugates and uses thereof

Country Status (8)

Country Link
US (5) US20160017058A1 (enExample)
EP (3) EP2968552B1 (enExample)
JP (1) JP6501270B2 (enExample)
CN (2) CN110420333A (enExample)
DK (1) DK2968552T3 (enExample)
ES (1) ES2790420T3 (enExample)
PT (1) PT2968552T (enExample)
WO (2) WO2014153002A1 (enExample)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189614A1 (en) * 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin related conditions
WO2018085617A1 (en) * 2016-11-07 2018-05-11 Argos Therapeutics, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
US9975949B2 (en) 2014-12-05 2018-05-22 Genentech, Inc. Anti-CD79b antibodies and methods of use
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10174124B2 (en) 2013-12-17 2019-01-08 Genentech, Inc. Anti-CD3 antibodies and methods of use
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
US10347379B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10360346B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived diagnostics
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
JP2019523753A (ja) * 2016-05-20 2019-08-29 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US20200405759A1 (en) * 2017-07-05 2020-12-31 Ucl Business Ltd Ror1 car t-cells
US20210139582A1 (en) * 2018-02-13 2021-05-13 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
US11084877B2 (en) 2014-09-12 2021-08-10 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
WO2021207770A1 (en) * 2020-04-11 2021-10-14 Northwestern University HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13Ra2
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
US11306142B2 (en) * 2017-07-05 2022-04-19 Ucl Business Ltd Bispecific antibodies to ROR1 and CD3
US11377496B2 (en) 2013-03-14 2022-07-05 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
CN115003798A (zh) * 2020-06-17 2022-09-02 兰迪·莱曼·阿伦 用于检测分析物的方法和试剂盒
US11453716B2 (en) 2016-05-20 2022-09-27 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
CN115368462A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11607453B2 (en) 2017-05-12 2023-03-21 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US11807692B2 (en) 2018-09-25 2023-11-07 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
US11866498B2 (en) 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US11976125B2 (en) 2017-10-13 2024-05-07 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US12084518B2 (en) 2015-05-21 2024-09-10 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US12252534B2 (en) 2016-02-04 2025-03-18 The Scripps Research Institute Humanized anti-CD3 antibodies, conjugates and uses thereof
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US12351643B2 (en) 2020-11-04 2025-07-08 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US12371504B2 (en) 2017-10-13 2025-07-29 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US12415860B2 (en) 2018-05-14 2025-09-16 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
US12492261B2 (en) 2020-11-04 2025-12-09 Genentech, Inc. Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EA201891502A1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
RU2015140915A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
BR112016009919A2 (pt) * 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
CN110845616A (zh) * 2014-03-21 2020-02-28 艾伯维公司 抗-egfr抗体及抗体药物偶联物
KR102411972B1 (ko) 2014-08-04 2022-06-23 에프. 호프만-라 로슈 아게 이중특이적 t 세포 활성화 항원 결합 분자
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
WO2016112870A1 (en) * 2015-01-16 2016-07-21 Tse-Wen Chang Molecular constructs with targeting and effector elements
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016168769A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
CA2986486C (en) * 2015-05-20 2023-03-07 Immunwork Inc. Molecular constructs with targeting and effector elements and their applications
KR102537102B1 (ko) * 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
US20180221508A1 (en) * 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN107849137B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
WO2017055392A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
EP3359191A4 (en) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
IL257696B2 (en) 2015-12-09 2024-11-01 Hoffmann La Roche Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
WO2017125897A1 (en) * 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US10259876B2 (en) 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
WO2017132103A2 (en) 2016-01-29 2017-08-03 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
FI3433280T3 (fi) 2016-03-22 2023-06-06 Hoffmann La Roche Proteaasin aktivoimia t-solubispesifisiä molekyylejä
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017218891A1 (en) * 2016-06-17 2017-12-21 Life Technologies Corporation Site-specific crosslinking of antibodies
WO2017219974A1 (zh) 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
CN109844105A (zh) 2016-07-11 2019-06-04 得克萨斯州大学系统董事会 包含硒代半胱氨酸的重组多肽及其产生方法
CA3034701A1 (en) 2016-08-30 2018-03-08 Board Of Regents, The University Of Texas System Production of seleno-biologics in genomically recoded organisms
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN108203718A (zh) * 2016-12-20 2018-06-26 上海生博生物医药科技有限公司 靶向EGFRvIII干扰PD-1降低肿瘤免疫逃逸的CAR-T载体及构建方法和应用
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
JP7153652B2 (ja) * 2017-01-31 2022-10-14 エフ．ホフマン－ラ ロシュ アーゲー 質量分析用の試薬
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3595719A4 (en) * 2017-03-16 2020-12-30 Immunwork Inc. LINKER UNITS AND MOLECULAR CONSTRUCTIONS WITH IT
SG11201907923VA (en) 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
AU2018251206A1 (en) 2017-04-14 2019-10-31 The General Hospital Corporation Chimeric antigen receptor T cells targeting the tumor microenvironment
EP3618867A4 (en) * 2017-05-02 2021-01-20 Cornell University METHODS AND REAGENTS FOR TUMOR TARGETING WITH IMPROVED EFFICIENCY AND REDUCED TOXICITY
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CA3090546A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CA3110647A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
JPWO2020071554A1 (ja) * 2018-10-05 2021-09-09 北海道公立大学法人 札幌医科大学 がん幹細胞特異的抗体
CN111744020B (zh) * 2019-03-27 2024-07-05 中国科学院宁波材料技术与工程研究所 一种主动靶向响应型多肽药物、其制备方法和应用
CN111995626B (zh) * 2019-05-27 2023-06-27 首都医科大学 6-(乙酰-aa-巯基)嘌呤,其合成,活性和应用
US20220251561A1 (en) * 2019-06-03 2022-08-11 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Eph2a aptamer and uses thereof
US20220354960A1 (en) * 2019-06-14 2022-11-10 The Scripps Research Institute Immune checkpoint blocking bispecific molecules
CN112110924B (zh) * 2019-06-21 2023-01-13 首都医科大学 6-S,9-N-(二乙酰-Lys-OBzl-巯基)嘌呤,其合成,活性和应用
CN112110925B (zh) * 2019-06-21 2023-06-27 首都医科大学 6-(乙酰-aa-巯基)嘌呤,其合成,与顺铂联用的活性和应用
CN112110923B (zh) * 2019-06-21 2022-08-05 首都医科大学 6-S,9-N-(二乙酰-AA-OBzl-巯基)嘌呤,其合成,活性和应用
CN112125905B (zh) * 2019-06-24 2023-04-07 首都医科大学 6-S,9-N-(二乙酰-Lys-OBzl-巯基)嘌呤、其合成、活性和应用
CN112125904B (zh) * 2019-06-24 2022-09-02 首都医科大学 6-S,9-N-(二乙酰-AA-OBzl-巯基)嘌呤、其合成、活性和应用
GB2607746B (en) * 2020-01-31 2025-05-21 Leiman Allen Randy Methods and kit for detection of analytes
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CN116249549A (zh) * 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
JP2023518902A (ja) * 2020-03-27 2023-05-08 イグザカ フランス 標的化ポリ（β－アミノエステル）
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
US20240043565A1 (en) * 2020-10-15 2024-02-08 Janux Therapeutics, Inc. Antibodies targeting psma and cd3 and uses thereof
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113018433B (zh) * 2021-03-11 2023-01-17 湖南大学 一种免疫药物及其在肿瘤免疫治疗中的应用
MX2023012408A (es) 2021-04-30 2023-10-31 Hoffmann La Roche Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US20100285037A1 (en) * 2007-10-17 2010-11-11 Arie Abo Antibodies to cll-1
US20140120096A1 (en) * 2012-09-27 2014-05-01 Merus B.V. Bispecific igg antibodies as t cell engagers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
IL160993A0 (en) 2001-09-21 2004-08-31 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7122622B2 (en) * 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
CN100477345C (zh) 2004-03-30 2009-04-08 株式会社吴羽 非水电解质二次电池用负极材料、其制造方法、负极和电池
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
WO2007058725A2 (en) 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
JP2009520949A (ja) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2632832A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN101384711A (zh) 2006-01-19 2009-03-11 Ambrx公司 具有经调节的免疫原性的非天然氨基酸多肽
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
WO2008077079A1 (en) 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20090102838A (ko) 2006-12-28 2009-09-30 암브룩스, 인코포레이티드 페나진 및 퀴녹살린 치환된 아미노산 및 폴리펩티드
CA2696627C (en) * 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2291659B1 (en) 2008-05-13 2015-09-16 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
DK2337846T3 (en) 2008-09-26 2018-03-12 Ambrx Inc NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES
WO2012098238A1 (en) 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
ME03440B (me) 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
US9796754B2 (en) 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
ES2898854T3 (es) 2011-05-27 2022-03-09 Ambrx Inc Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2968552B1 (en) 2013-03-14 2020-03-11 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
WO2014185985A1 (en) 2013-05-14 2014-11-20 Ambrx, Inc. Novel polypeptide small molecule conjugates and their uses
PL3004106T3 (pl) 2013-06-07 2018-01-31 Rhizen Pharmaceuticals S A Podwójne selektywne inhibitory kinaz pi3 delta i gamma
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
BR112016009919A2 (pt) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
KR102357961B1 (ko) 2013-12-17 2022-02-08 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
KR102891788B1 (ko) 2016-02-04 2025-11-26 더 스크립스 리서치 인스티튜트 인간화 항-cd3 항체, 접합체 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285037A1 (en) * 2007-10-17 2010-11-11 Arie Abo Antibodies to cll-1
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US20140120096A1 (en) * 2012-09-27 2014-05-01 Merus B.V. Bispecific igg antibodies as t cell engagers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bendig, M.M. Humanization of rodent monoclonal antibodies by CDR grafting. Methods: A Companion to Methods in Enzymology, 1995, Vol. 8, p. 83-93. *
Casset, F., et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Comm., 2003, Vol. 307, p. 198-205. *
MacCallum, R.M. et al. Antibody-antigen interactions: Contact analysis and binding site topography. J. Mol. Biol., 1998, Vol. 262, p. 732-745. *
Paul, W.E., Fundamental Immunology, 3rd Edition, 1993, p. 292-295. *

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377496B2 (en) 2013-03-14 2022-07-05 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
US11732054B2 (en) 2013-12-17 2023-08-22 Genentech, Inc. Anti-CD3 antibodies and methods of use
US12466896B2 (en) 2013-12-17 2025-11-11 Genentech, Inc. Anti-CD3 antibodies and methods of use
US10865251B2 (en) 2013-12-17 2020-12-15 Genentech, Inc. Anti-CD3 antibodies and methods of use
US10174124B2 (en) 2013-12-17 2019-01-08 Genentech, Inc. Anti-CD3 antibodies and methods of use
US11530275B2 (en) 2013-12-17 2022-12-20 Genentech, Inc. Anti-CD3 antibodies and methods of use
US11186650B2 (en) 2013-12-17 2021-11-30 Genentech, Inc. Anti-CD3 antibodies and methods of use
US10640572B2 (en) 2013-12-17 2020-05-05 Genentech, Inc. Anti-CD3 antibodies and methods of use
US11084877B2 (en) 2014-09-12 2021-08-10 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
US10360346B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived diagnostics
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10381117B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10380325B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10354757B2 (en) 2014-10-21 2019-07-16 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10354756B2 (en) 2014-10-21 2019-07-16 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10347379B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10803991B2 (en) 2014-10-21 2020-10-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10941199B2 (en) 2014-12-05 2021-03-09 Genentech, Inc. Anti-CD79b antibodies and methods of use
US9975949B2 (en) 2014-12-05 2018-05-22 Genentech, Inc. Anti-CD79b antibodies and methods of use
US12084518B2 (en) 2015-05-21 2024-09-10 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US12030947B2 (en) 2015-06-16 2024-07-09 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
US11192950B2 (en) 2015-06-16 2021-12-07 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
US11466087B2 (en) 2015-06-16 2022-10-11 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US12252534B2 (en) 2016-02-04 2025-03-18 The Scripps Research Institute Humanized anti-CD3 antibodies, conjugates and uses thereof
WO2017189614A1 (en) * 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin related conditions
JP2022064939A (ja) * 2016-05-20 2022-04-26 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11453716B2 (en) 2016-05-20 2022-09-27 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
JP7042467B2 (ja) 2016-05-20 2022-03-28 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
JP2019523753A (ja) * 2016-05-20 2019-08-29 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
JP7337204B2 (ja) 2016-05-20 2023-09-01 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
US11512288B2 (en) 2016-08-24 2022-11-29 Global Life Sciences Solutions Usa Llc Methods and kits for cell activation
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
WO2018085617A1 (en) * 2016-11-07 2018-05-11 Argos Therapeutics, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11607453B2 (en) 2017-05-12 2023-03-21 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11723925B2 (en) * 2017-07-05 2023-08-15 Ucl Business Ltd ROR1 CAR T-cells
US11306142B2 (en) * 2017-07-05 2022-04-19 Ucl Business Ltd Bispecific antibodies to ROR1 and CD3
US20200405759A1 (en) * 2017-07-05 2020-12-31 Ucl Business Ltd Ror1 car t-cells
US12371504B2 (en) 2017-10-13 2025-07-29 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US11976125B2 (en) 2017-10-13 2024-05-07 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US12297270B2 (en) 2018-02-08 2025-05-13 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US11866498B2 (en) 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US20210139582A1 (en) * 2018-02-13 2021-05-13 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
US12415860B2 (en) 2018-05-14 2025-09-16 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US11807692B2 (en) 2018-09-25 2023-11-07 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
WO2021207770A1 (en) * 2020-04-11 2021-10-14 Northwestern University HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13Ra2
CN115003798A (zh) * 2020-06-17 2022-09-02 兰迪·莱曼·阿伦 用于检测分析物的方法和试剂盒
US12351643B2 (en) 2020-11-04 2025-07-08 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US12492261B2 (en) 2020-11-04 2025-12-09 Genentech, Inc. Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CN115368462A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用

Also Published As

Publication number Publication date
EP2970505A1 (en) 2016-01-20
US20170002076A1 (en) 2017-01-05
WO2014153164A1 (en) 2014-09-25
ES2790420T3 (es) 2020-10-27
US20160115232A1 (en) 2016-04-28
US20220396621A1 (en) 2022-12-15
DK2968552T3 (da) 2020-04-14
US10351626B2 (en) 2019-07-16
WO2014153002A1 (en) 2014-09-25
EP2968552A1 (en) 2016-01-20
HK1219887A1 (zh) 2017-04-21
JP6501270B2 (ja) 2019-04-17
EP3721902A1 (en) 2020-10-14
EP2968552A4 (en) 2016-09-14
US11377496B2 (en) 2022-07-05
JP2016516061A (ja) 2016-06-02
CN105283201A (zh) 2016-01-27
CN105283201B (zh) 2019-08-02
PT2968552T (pt) 2020-05-18
EP2970505A4 (en) 2016-10-19
US20190315863A1 (en) 2019-10-17
EP2968552B1 (en) 2020-03-11
CN110420333A (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
US20160017058A1 (en) Bispecific antibodies and uses thereof
US20230355728A1 (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
CA3013463C (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
JP6637415B2 (ja) キメラ抗原受容体ｔ細胞スイッチおよびその使用
US20180100026A1 (en) Optimized chimeric receptor t cell switches and uses thereof
HK40016895A (en) Targeting agent antibody conjugates and uses thereof
HK1219887B (zh) 靶向剂抗体偶联物及其用途
HK40000405A (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK40000405B (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK1226751B (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
HK1226751A1 (en) Peptidic chimeric antigen receptor t cell switches and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, CHANHYUK;SCHULTZ, PETER G.;YOUNG, TRAVIS;AND OTHERS;SIGNING DATES FROM 20140429 TO 20140512;REEL/FRAME:032916/0631

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, CHANHYUK;AXUP, JUN Y.;SCHULTZ, PETER G.;AND OTHERS;SIGNING DATES FROM 20140420 TO 20140512;REEL/FRAME:032916/0477

AS Assignment

Owner name: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH,

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTING OF INVENTOR YU CAO PREVIOUSLY RECORDED ON REEL 032916 FRAME 0631. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNORS:KIM, CHANHYUK;SCHULTZ, PETER G;YOUNG, TRAVIS;AND OTHERS;SIGNING DATES FROM 20140605 TO 20140610;REEL/FRAME:033245/0243

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADD FIFTH INVENTOR PREVIOUSLY RECORDED AT REEL: 032916 FRAME: 0477. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:KIM, CHANHYUK;AXUP, JUN Y;SCHULTZ, PETER G;AND OTHERS;SIGNING DATES FROM 20140605 TO 20140619;REEL/FRAME:033245/0268

AS Assignment

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, CHANHYUK;AXUP, JUN Y.;SCHULTZ, PETER G.;AND OTHERS;SIGNING DATES FROM 20151006 TO 20151016;REEL/FRAME:036906/0588

Owner name: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, CHANHYUK;SCHULTZ, PETER G.;YOUNG, TRAVIS;AND OTHERS;SIGNING DATES FROM 20151006 TO 20151014;REEL/FRAME:036989/0418

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SCRIPPS RESEARCH INSTITUTE;REEL/FRAME:037161/0203

Effective date: 20151124

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SCRIPPS RESEARCH INSTITUTE;REEL/FRAME:039265/0571

Effective date: 20160607

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH;REEL/FRAME:048590/0059

Effective date: 20180927